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Abstract  
Oral cancer is most commonly referred to as cancer of the lip, oral cavity and oropharynx with 90% 
of oral malignancies being attributed to oral squamous cell carcinomas (OSCC). It is estimated that 
263, 900 new cases are diagnosed worldwide per year with 128,000 deaths being attributed to 
OSCC in 2008 alone. The survival rate has remained unchanged for last three decades at around 
50%, largely due to the delayed diagnosis of these cancers. Additionally, OSCC are often preceded 
by changes to the oral mucosa which can be detected on visual examination. Lesions which have 
the propensity to progress to malignancy are referred to as oral potentially malignant disorders 
(OPMD). Therefore, to improve patient outcomes there has been increased emphasis on detecting 
OSCC and OPMD at an earlier stage, 
New technologies which assist lesion visualisation have been made available to assist the general 
and specialist practitioner in detecting OPMD, and also differentiating OPMD from benign lesions. 
This thesis will focus on VELscopeTM, a device which utilises direct tissue autofluorescence to 
perform this function. When visualised with VELscopeTM, normal mucosa is associated with a pale 
green autofluorescence, while abnormal mucosa is associated with loss of autofluorescence (LAF).  
It is well reported in the literature that VELscopeTM is associated with high sensitivity for the 
detection of dysplasia but low specificity, and there are concerns regarding the presence of false 
positives due to inflammatory lesions also displaying LAF. In specialist practice, the device is 
effective in detecting dysplasia however it can be difficult to distinguish dysplasia from benign 
inflammatory lesions. Diascopic fluorescence, when the lesion returns to a normal fluorescence 
pattern under pressure, can help discern inflammatory lesions from those with malignant potential. 
Additionally, some cases of dysplasia may not display LAF. In general practice, the literature is 
limited however the main concerns are that relying on VELscopeTM alone may lead to gross over 
referrals.  
ii  
This thesis looks at addressing some of the concerns associated with the use of VELscopeTM in 
clinical practice to allow for greater uptake of this technology by both general and specialist 
practitioners. This thesis is divided into three discrete chapters. The first chapter reviews the 
literature regarding OPMDs and the various technologies available to assist in their earlier 
detection, and includes some literature regarding future developments in this area.  
The second chapter is an experimental chapter which investigates methods to utilise VELscopeTM 
for routine screening of patients in general dental practice. Patients presenting to the University of 
Queensland School of Dentistry were screened by a general dental practitioner utilising a decision 
making protocol whereby patients were first screened using conventional oral examination (COE) 
under incandescent light, followed by VELscopeTM and then by correlating the findings from these 
two examinations. In total, 305 patients were screened over a 19 month period. Using the decision 
making protocol proposed in this study and by incorporating VELscopeTM  into general dental 
practice allows for the detection of oral mucosal lesions requiring specialist referral without 
compromising patient care. 
To elucidate why some OPMD were associated with LAF, while other lesions with similar 
histology were not, the third chapter discusses potential underlying molecular mechanisms 
regarding LAF. Forty-three frozen tissue samples from archival material were correlated with 
clinical data regarding fluorescence characteristics. Relative gene expression was measured using 
Next Generation Sequencing (NGS) RNA-Seq and correlated with the clinical phenotype. No 
unifying genes related to LAF were identified. In dysplasia, LAF was associated with angiogenesis 
while blanching was related to inflammation. In keratosis/hyperplasia LAF was associated with cell 
proliferation and apoptosis while again blanching was related to inflammation. Biological causes 
for LAF were different between different histological groups but are associated with pathways 
related to angiogenesis, inflammation and cell cycle deregulation. 
iii  
This thesis demonstrates the utility of VELscopeTM in clinical practice, and how it can be 
effectively used in a general practice environment. Additionally, by uncovering molecular 
mechanisms underlying LAF, it is envisaged that further research can translate this into the clinical 
environment to reduce the rate of false positives and negatives allowing for more widespread use of 
VELscopeTM for the detection of OPMD. 
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Chapter 1: Introduction and literature review 
1.1 Introduction 
Oral cancer is most commonly referred to as cancer of the lip, oral cavity and oropharynx1 with 
90% of oral malignancies being attributed to squamous cell carcinomas.2 Traditional risk factors for 
oral squamous cell carcinomas (OSCCs) are the consumption of alcohol, tobacco and betel quid.2-5 
Recently, the Human Papilloma Virus (HPV) has been attributed as a causative factor in cancers of 
the base of the tongue, tonsils and oropharynx in patients which lack these traditional risk factors.6, 7  
Alcohol and tobacco have a synergistic effect with heavy drinkers and smokers having 38 times the 
risk of developing oral cancer compared to those who refrain from both. Oral cancer ranks as the 
sixth most common malignancy worldwide with an estimated 263, 900 new cases and 128, 000 
deaths in 2008 alone.8 Worryingly, current trends show an increase in the incidence of oral cancer 
among several populations regardless of an increase in knowledge about aetiological and risk 
factors for OSCCs.2 Despite technological advances in cancer therapies, the five year survival rate 
for oral cancer remains at 50% for most populations and has not changed significantly for the past 
three decades.2   
The poor prognosis for oral malignancies can largely be attributed to the late stage diagnosis of 
these cancers. Patients with a delayed diagnosis of oral or oropharyngeal carcinoma are 30% more 
likely to present with an advanced stage tumour compared to those without a delayed diagnosis.9-11 
The TNM classification system is widely used to delineate the extent and spread of a cancerous 
lesion and there is a significant decrease in prognosis with a more advanced TNM stage at initial 
presentation. The five year survival rates for stage I and II tumours are 85% and 66% respectively 
while this decrease for stage III and IV tumours to 41% and 9%.12 However almost half of all oral 
cancers are diagnosed at stage III or stage IV despite the fact that these lesions are in an area easily 
visualised by the medical or dental practitioner.9 As such, an emphasis should be placed on the 
earlier diagnosis of these cancers. 
2 
Squamous cell carcinoma is often preceded by lesions such as leukoplakia or erythroplakia which 
have the potential to progress to malignancy. Lesions which have the potential to progress to 
malignancy are referred to as oral potentially malignant disorders (OPMDs). The key to improved 
patient prognosis is believed to be through early detection of these lesions.13, 14 Detecting dysplastic 
changes at an early stage allows for active intervention before they progress to malignancy. Other 
conditions such as oral lichen planus (OLP) and submucous fibrosis are also considered to be 
potentially malignant disorders.15-18 There is also evidence that chronic hyperplastic candidosis may 
also induce dysplastic changes in oral epithelium.19, 20 Current practice for the detection of 
malignant or potentially malignant lesions involves a conventional oral examination (COE) with 
visual and tactile examination by the dental practitioner with leukoplakia or erythroplakic lesions 
considered suspicious for oral epithelial dysplasia (OED) or OSCCs.21-23 Induration and fixation in 
particular are tactile signs which may suggest an oral malignancy. To confirm the diagnosis, these 
are usually referred to a specialist centre for biopsy of the lesion for a definitive diagnosis and 
management of the condition. A biopsy is considered the gold standard for the diagnosis of OED 
and OSCCs as it allows for a thorough evaluation of the epithelial architecture of the lesion.24 For 
OPMDs such as OLP, current practice is to recall the patients regularly and observe for any 
changes, such as loss of homogeneity, which may indicate carcinogenesis and to biopsy the lesion 
as indicated.25, 26  
However observation of any such change is highly clinician dependent and even with meticulous 
follow up, early malignant changes may be overlooked.27 In addition, histological changes 
indicative of dysplasia can be found even in clinically normal mucosa. 28, 29 While screening 
programmes to identify malignant lesions have been trialled, their cost effectiveness in the general 
population is uncertain and the onus has fallen on primary care providers to screen patients for such 
lesions.30-33 Currently the US preventive task force states that there is insufficient evidence to assess 
the balance of benefits or harm of routine screening for oral cancer.34 Of concern, a meta-analysis 
has indicated that a COE while having a relatively high sensitivity at 93%, has a poor specificity at 
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31% and cannot reliably differentiate between benign and dysplastic lesions.28 Analysis states that a 
number of benign conditions mimic oral malignancies and dysplasia may be found in clinically 
normal mucosa.28 The review suggests that further research should be undertaken into adjunct 
technologies to improve the reliability of clinicians in screening for malignant and potentially 
malignant disorders.28  These devices use the principles of vital staining, reflectance or tissue 
autofluorescence and aim to enhance visual detection of lesions and to differentiate between benign 
and malignant lesions.6 This concept is utilised in commercially available devices such as toluidine 
blue, ViziLite PlusTM, Microlux/DLTM, Orascoptic DKTM, VELscopeTM, IdentafiTM, DOE SE KitTM 
and Sapphire PlusTM.35-42 The aims of these products are twofold; firstly to aid the practitioner in the 
detection of potentially malignant lesions; and secondly to highlight areas of clinically visible 
lesions which are most likely to have undergone dysplastic changes. This could assist determine the 
ideal site of biopsy and also the margins of the lesion to determine the extent of excision required. 
This review discusses the current literature regarding OPMDs and the efficacy of these systems as 
adjuncts for detecting malignant lesions or potentially malignant disorders for the general dental 
practitioner. 
1.2 Oral potentially malignant disorders (OPMDs) 
1.2.1 Leukoplakia 
Oral leukoplakia is defined by World Health Organization (WHO) as a “A white plaque of 
questionable risk having excluded (other) known diseases or disorders that carry no increased risk 
for cancer”.43 It is the most common OPMD when OSCCs are concerned. Using a pooled analysis, 
the estimated global prevalence of leukoplakia is approximately 2% although this figure is likely to 
be an overestimation.22, 44 Leukoplakia is six times more prevalent in smokers, and alcohol use is 
also a risk factor in its development.22  
Clinically, leukoplakia may be classified as either homogenous or non-homogenous. This 
distinction is based upon surface colour and morphological characteristics. A lesion is considered 
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homogenous if it is flat, thin and uniform in colour.15, 22 A non-homogenous leukoplakia contains 
red areas although remains predominantly white and may be speckled or nodular.15, 22 A non-
homogenous leukoplakia is associated with a greater risk of malignant transformation.15, 23, 45 A 
change in clinical diagnosis from a homogenous to non-homogenous leukoplakia was associated 
with a 4.2 times increase in the risk of a histological diagnosis of dysplasia on biopsy.23 
While the malignant potential of oral leukoplakia is undisputed, the reported rate at which this 
occurs varies greatly. A hospital study in Netherlands found an annual transformation rate of 2.9% 
while a recent study in China reported a rate of 3.38%, both of which are higher than previous 
estimates.45, 46 In Australia, the annual malignant transformation rate was calculated to be 
approximately 1% .47 Interestingly, while smokers have a higher rate of leukoplakia, in established 
lesions, there is a higher malignant transformation rate in non-smokers particularly among 
women.22, 45, 48 Women in general seem to have a higher risk of malignant transformation of oral 
leukoplakia.45  
Currently, the only clinical predictor for the risk of malignant potential is whether or not the lesion 
is homogenous. Histologically, as defined by the WHO, oral leukoplakia may be classified as 
hyperplasia, mild dysplasia, moderate dysplasia, severe dysplasia or carcinoma in situ.43 A higher 
grade of dysplasia is associated with an increased risk of malignant potential.22, 45 Liu et al proposed 
a new approach to classifying lesions as either ‘high risk’ or ‘low risk’ according to the number of 
characteristics of epithelial dysplasia the lesion displayed on histological analysis.46 A high risk 
lesion was one which displayed at least four architectural changes and five cytological changes on 
histological analysis. It was found that a high risk lesion had a 4.57 fold increased rate of malignant 
transformation. This approach provides a less arbitrary method of classification since it is known 
that there is a large amount of inter-operator variability in determining the degree of dysplasia using 
traditional methods.  
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1.2.2 Erythroplakia 
Erythroplakia has been defined as a fiery red patch which cannot be characterized clinically or 
pathologically as any other definable disease.15, 22, 43 The reported prevalence varies between 0.02% 
and 0.2%.49 The lesion may be flat or depressed and is predominantly on the floor of mouth, soft 
palate, ventral tongue and tonsillar fauces.49 Generally, the lesion is a solitary one which helps 
distinguish the condition from other systemic conditions.22 While the condition is not as prevalent 
as leukoplakia, on biopsy it frequently demonstrates epithelial dysplasia. In one study, from 65 
biopsies of erythroplakia, 51% displayed invasive squamous cell carcinoma while a further 40% 
were carcinoma in situ highlighting the seriousness of the condition.50 Of those which display 
epithelial dysplasia a large proportion undergo malignant transformation.22 They may also present 
as mixed white/red lesions which are termed erythroleukoplakia.15 
1.2.3 Oral Lichen Planus 
Oral lichen planus is a T-cell mediated chronic inflammatory condition of the oral mucosa. It is 
characterised by a subepithelial lymphocytic infiltrate leading to degeneration of basal cell 
keratinocytes although the stimulus for immune activation is currently unknown.51 OLP has varying 
clinical presentations with the reticular, atrophic and erosive forms being the most common 
although multiple forms may present concomitantly and clinical presentation of the lesion may 
change over time.52 Lichen planus may also have extra-oral involvement with vaginal and 
cutaneous lesions being the most common.53, 54 Typically, the condition presents with bilateral and 
symmetric lesions.53 Symptoms may vary from completely asymptomatic to severe pain and 
discomfort which prevents proper intake of food. Factors such as stress, systemic illnesses, certain 
foods, poor oral hygiene or dental treatment may exacerbate the condition in some cases.52 
Currently, treatment for the condition is largely symptomatic through the use of topical 
corticosteroids to suppress inflammation. Asymptomatic cases generally do not require any 
management other than periodic follow-up.  
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Of much controversy is the malignant potential of OLP. Many authors have argued that a small 
percentage of cases of OLP progress to oral squamous cell carcinoma. The reported rate at which 
this occurs varies from 0 to 10% although around 1% is the commonly quoted figure.25, 53, 55-58 It is 
known that chronic inflammation may lead to malignancy as seen with the development of 
colorectal cancer in inflammatory bowel diseases and oesophageal carcinoma after esophagitis 
among others.51 This may be due to damage to DNA, disruption of tissue architecture and function 
via activation of stromal cells and components or due to changes in the extracellular matrix. An 
over-expression of p53 has also been noted in OLP lesions however this may be a response to 
damage due to chronic inflammation.26  
Many authors have observed that OSCCs arising in OLP have different behavioural characteristics 
to regular OSCCs which suggests that molecular events leading to malignancy may differ from 
classical epithelial dysplasia.51 OSCCs arising in OLP has been found in patients without classical 
risk factors such as alcohol and smoking and seems to be more common in women.25, 26, 59 There is 
reportedly a higher rate of secondary tumour formation in OSCCs arising from OLP compared with 
oropharyngeal cancer without a previous diagnosis of OLP with Mignogna et al finding at least one 
secondary tumour in 53% of OSCCs arising from OLP.60 These findings have lead Mignogna et al 
to propose that OLP could cause field cancerization of the oral mucosa.61 It is theorised that the 
chronic inflammation may cause widespread changes in the oral mucosa, increasing its propensity 
to develop OSCCs. It is known that chronic inflammation can be seen histologically in clinically 
normal tissue around lichenoid lesions.62 This may explain both the high rate of secondary tumours 
and also the development of OSCCs in oral mucosa distant to the primary OLP lesion. OSCCs 
arising in lichen planus also displayed a greater tendency to metastasise with microinvasive 
carcinomas of 1.75mm displaying nodal involvement when generally this does not occur until 
greater than 4mm of invasion has occurred.25, 63 
Due to the small risk of malignant change, current ideology is to periodically recall patients 
diagnosed with OLP to detect any malignant changes at an early stage. However the effectiveness 
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of this protocol itself has been questioned.55, 64 A significant problem exists in that there is no 
definitive method of knowing if malignant change has occurred without taking a biopsy of the 
lesion. Currently, a biopsy may be taken if there are visible changes, such as loss of homogeneity, 
which indicate progression to malignancy, however studies have found little if any difference in 
presentation of lichenoid lesions which do and do not proceed to malignancy.25, 60 Further, many 
OSCCs found on follow up of OLP have been in sites other than those which were initially biopsied 
which further highlights difficulties in identifying early malignant changes.53 When comparing a 
follow up period of 4 months and 12 months, there was no reduction in mortality from OSCCs 
arising in patients with OLP although tumours were diagnosed at an earlier stage.25, 65 In one 
publication, even a four month follow up with periodic biopsies resulted in a 50% mortality rate 
among six patients who were diagnosed with OSCCs on follow up.27 This may be due to either 
failure to detect malignant changes or rapid progression of the lesion to malignancy.  
Due to these findings and the low rate of malignant transformation, specialist follow up does not 
seem cost effective.64 A large part of the failures of screening seem to be the lack of definitive 
criteria on what to biopsy. Currently it is largely clinician dependant and dysplastic changes may 
easily be overlooked. A similar situation can be seen with screening for gastric and colon cancers. 
When a new criterion was introduced for gastrointestinal endoscopic surveillance in western 
countries, the early diagnostic rates of these cancers increased.27 Future areas of research may be to 
more easily discern and identify which areas of the mucosa are more likely to proceed to 
malignancy. Zhang et al found that toluidine blue is more likely to stain dysplastic lesions which 
proceed to malignancy than those which do not.66 This could prove to be of use if similar effects 
were found in lichenoid lesions. Use of devices such as VELscopeTM may also aid in the detection 
of dysplasia in patients with OLP. 
While the argument of the malignant potential of OLP has for some time been controversial, this 
was further complicated by the proposition by Krutchkoff and Eisenberg of a distinct 
histopathological entity referred to as lichenoid dysplasia.67 Krutchkoff claimed that cases of 
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malignant transformation of OLP were initially cases of dysplasia with lichenoid inflammation 
which was misdiagnosed on initial histological analysis due to their similarities.68 This was based 
on a review of reported cases of malignant transformation of OLP of which many, on retrospective 
analysis, displayed dysplasia on the initial biopsy. This separate entity was labelled lichenoid 
dysplasia, however no consensus on the topic has been reached. It is unknown if this is a dysplastic 
change due to chronic inflammation which would represent true malignant transformation or if the 
dysplasia was always present and the diagnosis was complicated due to the presence of a 
subepithelial lymphocytic infiltrate. It is also possible that the inflammatory infiltrate is an immune 
response to the dysplastic changes if tumour cells are detected.69 Much of the difficulty may arise 
due to the difficulty in histological diagnosis of OLP. It has been shown that if over-riding 
characteristics of lichen planus are present on a histological specimen, dysplasia may easily be 
overlooked and dysplastic characteristics may be disregarded as reactive changes to inflammation.70 
Further to this, OLP itself displays many features which are characteristic of epithelial dysplasia 
even when dysplasia is not present.70, 71 Due to these similarities, there is a high level of 
interobserver variability in the histological diagnosis of OLP and it is proposed more stringent 
criteria may be required.72  
Zhang et al performed molecular analysis of OLP lesions to determine if there was a loss of 
heterozygosity (LOH) in these lesions which may indicate malignant changes in these lesions. It 
was found that LOH in lesions diagnosed as OLP is similar in LOH to reactive lesions rather than 
dysplasia indicating that oral lichen planus itself does not have a malignant risk.73, 74 However a 
similar analysis in lesions diagnosed as lichenoid dysplasia found similarities in LOH to epithelial 
dysplasia giving further weight to the argument that it is lichenoid dysplasia, not OLP itself which 
has a malignant potential.75  
With the available evidence, the malignant potential of oral lichen planus still remains unclear. It is 
unknown if OLP itself has a propensity to develop into OSCC or if there is indeed a separate entity 
referred to as lichenoid dysplasia. Since with current techniques it is impossible to predict which 
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patients with OLP will develop OSCCs and due to the aggressive nature of OSCCs arising in this 
cohort, the safest option seems to be to review cases periodically to maximise the chance of 
detecting malignant changes at an early stage. Future areas of research could look at clinical 
adjuncts, such as VELscopeTM, to distinguish those areas of lichenoid lesions with malignant 
changes to aid the clinician. The availability of histological features or molecular markers 
highlighting those OLP lesions which are at a high risk of malignant change would also be of great 
benefit as this could allow for targeted follow up.  
1.2.4 Chronic hyperplastic candidiasis 
Candida is a commensal organism found in the oral microflora of 40% of the population with 
Candida albicans being the most common among these.20 While in the majority of cases they do 
not cause harm, in the correct environment, such as if the patient is immunosuppressed, they may 
become pathogenic. There have also been suggestions that candidal infection may predispose to 
malignant transformation of the oral epithelium, particularly in cases of chronic hyperplastic 
candidiasis. Chronic hyperplastic candidosis typically presents as “an adherent chronic white patch 
on the commissures of the oral mucosa”.76 
It has been shown that in patients with epithelial dysplasia, the degree of dysplasia correlates with 
higher amount of yeast in the oral cavity.20 Another study found an association between 
histologically confirmed fungal infection and epithelial dysplasia.77 This study also found that 
among patients diagnosed with epithelial dysplasia, 21.9% of lesions with a concurrent fungal 
infection progressed in the severity of dysplasia compared with 7.6% of those without fungal 
elements.77 Nagy et al found in a cohort of 21 patients with OSCCs that 8 of these had candidal 
infection on the tumour site itself while none of them presented with candidal infection on a control 
site.78 It is estimated that candidal leukoplakias progress to malignancy in 9-40% of cases.79  
The reason for malignant transformation of the oral mucosa hasn’t yet been determined. It is 
possible that Candida itself may produce carcinogens which lead to point mutations in the 
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epithelium.76 Certain strains of C. albicans have been shown to be able to convert ethanol into 
acetylaldehyde, an established carcinogen.80 Localised increases in concentration of acetylaldehyde 
may initiate malignant changes in the oral epithelium. It is also possible that C. albicans does not 
initiate or exacerbate the malignant process but simply that dysplastic epithelium provides a 
favourable environment for the species to grow in. While the link between chronic hyperplastic 
candidosis and oral malignancy has not been established, an association between the two seems 
likely and further research is required. 
1.3 Oral lesion visualisation aids 
1.3.1 Toluidine blue 
Tolonium chloride, more commonly known as toluidine blue, has been proposed as a tool for 
delineating malignant and potentially malignant lesions of the cervix and subsequently the oral 
cavity since the 1960’s. Toluidine blue is a metachromic stain with affinity for DNA and RNA.81 
Areas of epithelial dysplasia contain a greater amount of DNA and RNA than normal tissue which 
correlates with an increased uptake of toluidine blue.81 The dye is available as a mouth rinse to find 
any lesion in the oral cavity or as a swab form which can allow visualisation of specific areas.82 In 
vivo, uptake of blue stain is associated with dysplastic tissue while lack of stain uptake is associated 
with benign lesions or normal mucosa.83 Studies have reported partial, equivocal, or a speckled 
pattern of stain uptake and also identified varying intensities of stain uptake and variably classify 
these as positive or negative.84 While extensive research on the use of toluidine blue for identifying 
OPMDs is available, opinion on its efficacy and justification for routine use of the stain is divided 
among experts.  
Initially, toluidine blue was assessed for its efficacy in highlighting OSCCs. Multiple studies have 
found a high efficacy of toluidine blue in detecting OSCCs reporting 100% uptake of the dye.81, 82, 
85-87
 This provides strong support for routine use of toluidine blue in specialist practice, however 
ideally these lesions would be detected before invasion has occurred. In cases of OSCCs seen in 
11 
specialist practice, staining characteristics are unlikely to alter the decision to biopsy therefore more 
consideration needs to be given to toluidine blue’s performance in delineating dysplasia rather than 
its efficacy in highlighting OSCCs. Margin studies for resection of OSCCs have found that while 
toluidine blue will stain the tumour centre, it failed to identify the presence of dysplasia and 
carcinoma-in-situ on resection margins.81 
A number of groups have assessed the efficacy of toluidine blue for detecting OED in patients 
referred to specialist centres. Significant variation in accuracy of the technique is seen with reported 
sensitivities ranging from 50 – 100%82, 85, 86, 88-91 and specificities ranging from 30 – 79% 82, 85-91. 
Warnakulasuriya and Johnson reported the detection of five additional areas of dysplasia in 102 
patients using OraScanTM, a commercially available toluidine blue mouth rinse supporting its use in 
specialist centres.86 The large variation in reported sensitivities may be due to the patient population 
and lesion exclusion criteria as inclusion of a large number of invasive carcinomas may increase the 
reported sensitivities while inclusion of early dysplasia may decrease the sensitivity. Toluidine blue 
appears to have a higher rate of take up with increasing severity of dysplasia which can be 
considered to be ‘high risk’ and a large number of false negatives may be attributed to earlier stages 
of dysplasia.82, 91 However, mild and moderate dysplasia may also proceed to malignancy and 
should be considered significant pathology. If toluidine blue alone was used to determine lesions to 
biopsy, these areas may be overlooked. The relatively low specificity is also of concern and may be 
attributed to inflammatory lesions which can also have rapid cell division increasing dye uptake.91 
For this reason, it has been proposed that reviewing lesions which appear benign but have with 
uptake of dye may allow for reduction in false positives. 86, 91 Currently, no literature is available 
which has assessed this hypothesis.  
Molecular studies support the previous hypothesis that uptake of toluidine blue is associated with 
‘high risk’ lesions. Epstein et al found that toluidine blue uptake was associated with higher risk 
molecular profiles and increased allelic loss.92 This is in agreement with Zhang et al who found 
lesions with increased rates of loss of heterozygosity in lesions which stained positively.66 In 
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addition to this, toluidine blue positive lesions were associated with greater rates of malignant 
transformation and also earlier transformation.66 Further studies are required to determine the 
clinical significance of these findings. 
Thus far, only one study has been conducted to assess the ability of toluidine blue to detect 
dysplastic lesions in general practice. Patients were invited to a mass screening programme aimed at 
detecting five neoplasms prevalent in the local community. 7957 subjects participated in the 
Toluidine blue arm of the trial, 4080 in the experimental group and 3895 in the control group using 
a placebo dye.93 Those without high risk factors for oral carcinoma such as alcohol and betel quid 
were excluded from this study. Overall, two cases of oral cancer were ascertained in the 
experimental group and three in the control group. There was no significant difference in the 
detection of potentially malignant lesions between the two groups. Further, a five year follow-up of 
participants in the National Cancer Registry and National Household Registry found an additional 
three cases of oral cancer in both groups which suggests that screening with toluidine blue did not 
increase the rate of oral cancer detection. While this trial was conducted on those with high risk 
habits for oral cancer limiting the generalizability for a dental practice, this is likely to be the target 
population for potential oral cancer screening programs. Although the five year follow-up may not 
be enough to detect a reduction in the incidence or mortality rates for oral cancer, the ultimate aim 
of cancer screening programmes, this initial data indicates no advantage of a toluidine blue rinse 
over the placebo dye in the detection of potentially malignant lesions.  
Overall, toluidine blue seems to be an effective aid in delineating invasive carcinomas but not for 
the detection of potentially malignant lesions. Current evidence suggests it may be useful in a 
specialist care environment to help raise suspicion of lesions which may not otherwise be 
investigated or in the follow up of patients with a history of oropharyngeal cancer.81, 85, 89, 90 
Although toluidine blue does not accurately stain dysplasia, especially at its early stages, molecular 
analysis has suggested that lesions which retain toluidine blue are more likely to contain high risk 
molecular profiles and are more likely to progress to malignancy.66, 92 This warrants further research 
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in establishing the use of toluidine blue for predicting the risk of malignant transformation of 
established lesions referred for specialist care however currently the evidence does not support the 
use of toluidine blue in screening for OPMDs in the general population. 
1.3.2 ViziLiteTM 
ViziLiteTM (Zila Inc., CO, USA) is a commercially available kit utilizing the principles of 
chemiluminescence to enhance the visibility and detection of oral potentially malignant lesions. 
Like toluidine blue, the principles on which ViziLite is based are adopted from similar technologies 
used in the detection of cervical cancer. The system utilises a 1% acetic acid mouth rinse followed 
by visualisation of the oral cavity under a chemiluminescent light source. The ViziLite light stick is 
bent breaking the glass inside and resulting in chemiluminescence emitting a bluish-white light with 
a wavelength ranging from 430 – 580nm.94 The manufacturer claims that following the application 
of acetic acid wash, mucosal abnormalities are better visualised due to changes in their refractile 
properties and are seen to be ‘aceto-white’ as compared to normal epithelium which appears as a 
blue hue.37 A newer system, ViziLite TblueTM, uses the same chemiluminescent system but 
recommends follow up of ‘aceto-white’ lesions with TBlue, a toluidine blue swab, to further 
visualise the lesion.37 
Currently, evaluation of ViziLite has been limited to specialist centres. A number of authors have 
reported that ViziLite enhanced visualisation of lesions based on characteristics such as ease of 
visibility, texture, brightness or sharpness of lesions.36, 95-99 However Oh and Laskin believe that the 
use of ViziLite hindered visualisation of lesions, while acetic acid mouthwash itself, without the 
addition of chemiluminescence may aid lesion visualisation.100  
While ViziLite has not been marketed as a diagnostic aid, but rather designed to help visualisation, 
studies assessing its efficacy in detecting dysplasia and OSCCs have reported sensitivities between 
77.1 – 100% and  specificities from 0 – 30%.36, 99, 101, 102 Conversley, Mehrothra et al found four 
cases of dysplasia among 102 patients all presented negative using ViziLite.103 Concerns with the 
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ViziLite system are that almost any white lesion appears as a positive and a number of benign 
conditions such as leukoedema or hyperkeratosis are also likely to appear ‘aceto-white’.36, 104 With 
this in consideration, ViziLite doesn’t seem to provide any benefits in differentiating OPMDs from 
benign lesions since any white area can appear positive. Further, it is reported that red lesions are 
less likely to be detected under ViziLite than with incandescent light alone.95, 97 This is a significant 
finding considering that erythroplakia is highly associated with dysplasia and these may be missed 
using ViziLite alone for lesion detection. Rajmohan et al stated that ViziLite was effective in 
delineating precancer or cancer which presented as either keratotic or mixed red-white lesions 
however failed to detect lesions, including an OSCC, which presented as erosive lesions.105 
Originally ViziLite was marketed on its own, however to enhance the detection of lesions, Zila 
Pharmaceuticals releaseed a new system now called ViziLite TBlueTM which includes the addition 
of a toluidine blue swab to help further differentiate lesions.37 Epstein et al found using 
chemiluminescence all cases of serious pathololgy were more easily visualised.96 The authors found 
that among 97 lesions, all 20 cases of severe pathology tested positive with toluidine blue however 
their definition of severe pathology only included OSCCs, carcinoma-in-situ or severe dysplasia. In 
cases of mild and moderate dysplasia, 59% of cases stained positive with toluidine blue. The 
authors argue using this system would result in a 55% reduction in biopsies by only biopsying 
lesions which retain the dye. However, using this protocol a number of lesions with mild and 
moderate dysplasia would be missed. Considering that mild and moderate dysplasia can also 
progress to malignancy, these should be considered significant pathology. Kämmerer et al found 
while toluidine blue reduced false positives without increasing false negatives, there is little clinical 
evidence to justify the additional cost of the system for diagnosis of suspicious lesions. 
Current evidence indicates that ViziLite doesn’t enhance the early detection of OPMDs or OSCCs. 
While lesion visualisation may be enhanced using ViziLite, it is unlikely to alter the decision to 
biopsy or result in an increase in the detection of OPMDs.36, 99 Further, the low specificity of 
ViziLite is likely to be exemplified in general dental practice where the prevalence of OPMDs is 
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much lower than a specialist centre. In addition to this, ViziLite only aids the visualisation of white 
lesions while erythroplakic or erosive lesions may be missed.97, 101, 105 Considering the low accuracy 
of toluidine blue as previously discussed, this addition is un likely to be of any benefit. Current 
literature does not support the use of ViziLite or ViziLite TBlue in the detection of OPMDs or 
OSCCs. 
1.3.3 Microlux/DLTM 
Microlux/DLTM (AdDent, Inc.) is a light based system sharing the same principles as ViziLite. 
Instead of chemiluminescence, Microlux emits a white light through an LED transilluminator. Like 
ViziLite, the manufacturer recommends the use of a 1% acetic acid rinse before use to alter the 
refractile properties of the mucosa after which leukoplakic lesions appear ‘aceto-white’ under 
Microlux.40 Currently only one clinical evaluation of Microlux/DL is available. 
McIntosh and colleagues evaluated Microlux/DL on 50 patients referred to an oral medicine 
specialist for assessment of an oral lesion.35 Following a conventional oral examination under 
incandescent light, patients were examined with Microlux/DL without the use of an acetic acid 
wash and then again following the mouth rinse. This was compared to an LED headlight which also 
employs white light and is commonly used by dental practitioners. Microlux/DL increased lesion 
visibility in 64% of cases and provided a sensitivity and specificity of 77.8% and 70.7% when 
compared against a histopathological gold standard. While lesion visibility was enhanced compared 
to a regular incandescent light, Microlux/DL did not uncover any new lesions or alter the 
provisional diagnosis or biopsy site. It was also poor in discriminating between benign lesions and 
OPMDs or oral malignancies. The LED headlight displayed similar properties to Microlux/DL in 
increasing lesion visibility and allowed for a greater field of view. As such, with the evidence 
available, Microlux/DL cannot be advocated for use in the detection of OPMDs or OSCCs. 
However this study did highlight that white light may be beneficial compared to routine 
incandescent operatory lights in the detection of oral lesions.  
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1.3.4 Autofluorescence  
Autofluorescence is a phenomenon whereby an extrinsic light source is used to excite endogenous 
fluorophores causing the natural emission of light from these compounds. Endogenous fluorophores 
include certain amino acids, metabolic products and structural proteins among others.106 The 
excitation and emission wavelength varies greatly between fluorophores. Within oral mucosa, the 
most relevant fluorophores are NADH, FAD and collagen. NADH and FAD are metabolic products 
and are believed to be responsible for autofluorescence of epithelium.107 Stromal fluorescence has 
been associated with crosslinks within the collagen matrix.107 Autofluorescence may be utilised in 
both an in vitro and in vivo manner. Multiple oncological applications for in vivo fluorescence 
spectroscopy have previously been described.108 
Within cervical epithelium, using UV excitation Pavlova et al found a decreased fluorescence 
within the stroma with epithelial dysplasia using fluorescence microscopy.109 Drezek et al 
performed confocal microscopy studies using excitation at 380nm and 460nm within cervical 
epithelium.110 At 380nm the epithelium displayed an increase in fluorescence with epithelial 
dysplasia however like the previous study, stromal fluorescence decreased.110 With a 460nm 
excitation source, stromal fluorescence was again shown to decrease with dysplasia but with no 
significant difference in epithelial fluorescence.110  This property has been translated into direct 
clinical applications with the advent of direct tissue fluorescence. Using wavelengths in the 375-
440nm spectrum, in vivo autofluorescence could differentiate between grades of cervical 
intraepithelial neoplasia (CIN) with a high degree of sensitivity but could not differentiate between 
inflammation and CIN.111 Excitation with a 355nm wavelength has also been found to be highly 
sensitive.112 
Confocal microscopy analysis of the oral mucosa finds similar results to those in the cervix. Using 
UV excitation, in the epithelium itself autofluorescence increased slightly in dysplasia however was 
associated with a decrease in inflammatory lesions.107 However, both dysplasia and inflammatory 
lesions were associated with a loss of stromal fluorescence using excitation with both UV and a 
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488nm wavelength.107 Using Monte-Carlo modelling, inflammation seems to show a greater loss of 
autofluorescence than dysplasia since it occurs at both the stromal and epithelial level.113 Other 
investigators have found using an excitation wavelength of 410nm and emission wavelength of 635 
nm can differentiate oral lesions with a high degree of sensitivity and specificity.114 Commercial 
devices have become available for in vivo detection of epithelial dysplasia in the oral mucosa and 
these are described in greater detail below.115  
1.3.4.1 VELscopeTM 
VELscopeTM (LED Medical Diagnostics Inc., Barnaby Canada) uses the principles of 
autofluorescence to differentiate benign mucosa from malignant and potentially malignant 
lesions.116 VELscopeTM utilises blue light excitation in the 400-460nm wavelength.6, 117-119 At this 
excitation wavelength, normal oral mucosa is associated with a pale green fluorescence while 
abnormal tissue is associated with a loss of autofluorescence (LAF).6 Pilot studies found that this 
excitation wavelength could be used in vivo to differentiate normal oral mucosa from dysplasia, 
carcinoma-in-situ and invasive carcinoma and the manufacturer extrapolated these findings to claim 
that VELscopeTM may be used to detect oral mucosal abnormalities not visible under white light 
examination.116, 120  
Early research supporting the use of VELscopeTM was based on case reports conducted on patients 
referred to or on a follow up programme at specialist oral dysplasia clinics.121, 122 Kois et al found 
VELscopeTM assisted in the detection of dysplastic and malignant lesions not visible under COE 
and helped raise suspicion of lesions which would otherwise not be subjected to biopsy.121 For 
example, in one case where wide spread erythema was present confounding the operator on which 
areas to investigate, VELscopeTM revealed an area which later proved to be a well differentiated 
carcinoma. It can also be a valuable tool in demarcating margins of established tumours where the 
malignant tissue may be beyond what is otherwise clinically visible.123 Poh et al found LAF 
extended beyond the clinically visible lesion in 19/20 tumours, in one case extending 25mm beyond 
the tumour boundary.123 Histological and molecular analysis of 36 biopsies in areas with LAF 
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beyond the clinically visible tumour contained either dysplasia/cancer on histology and/or genetic 
alterations associated with molecular risk in 35 specimens.123 While these case reports were in a 
specialist environment, they provided initial evidence that VELscopeTM could differentiate 
dysplasia from normal oral mucosa. 
The diagnostic accuracy of VELscopeTM in detecting dysplasia and OSCCs has been studied 
extensively in specialist referral centres.103, 124-128 It appears that VELscopeTM is efficacious in 
detecting oral epithelial dysplasia and OSCCs with reported sensitivities ranging from 30 to 
100%.103, 124-129 VELscopeTM may also uncover additional dysplastic lesions missed under COE.126, 
127
 For this reason, VELscopeTM appears to be a valuable tool in the follow up of patients with a 
history of head and neck cancer. However, Mehrotra et al argue that since not all dysplastic lesions 
display a loss of fluorescence, its use in routine practice should be discouraged as it may lead to a 
false sense of security and these lesions may be ignored.103 Of concern, VELscopeTM appears to 
have a high rate of false positives with reported specificities between 15.3 to 80.8%.103, 124-129 This 
suggests that VELscopeTM is a poor differentiator between benign and dysplastic lesions.125, 128 In 
particular, inflammatory lesions can also display LAF and act as confounders when using 
VELscopeTM.127 In general practice, the majority of oral mucosal lesions seen are benign in nature 
and overestimation of oral mucosal abnormalities may lead to patient harm through unnecessary 
biopsies and referrals. 
While the majority of studies have evaluated VELscope’s diagnostic capabilities and accuracy 
without taking into account clinical characteristics, VELscope’s main function is to be an adjunctive 
aid to, rather than a replacement for COE. For this reason, Farah and colleagues prospectively 
evaluated what additional benefits VELscopeTM provides when used in conjunction with COE in a 
specialist environment.127 Farah et al also assessed for diascopic fluorescence. Diascopic 
fluorescence refers to phenomenon whereby lesions which display LAF return to a normal 
fluorescence pattern when pressure is applied. It is suggested that this can be used to differentiate 
inflammatory lesions from those with overt dysplasia.127 Lesions which displayed complete 
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diascopic fluorescence were considered negative for LAF. When combined findings of 
VELscopeTM and COE were considered, the sensitivity was shown to be higher than for either 
examination alone without a large drop in specificity.127 This suggests the importance of clinical 
interpretation when using VELscopeTM rather than relying on LAF findings on its own. However, 
this was performed by specialists and it is suggested that advanced knowledge of oral mucosal 
pathology is required to effectively interpret VELscopeTM findings and this may not be within the 
scope of general practitioners.124, 125, 127  Interpreting VELscopeTM findings itself can be difficult 
with concerns that what constitutes LAF compared to diminished autofluorescence is arbitrary and 
may be vulnerable to inter-operator variability.124 Farah et al  observed that blanching of lesions is 
difficult to achieve and partial blanching in particular may complicate interpretation.127 
So far, research on the use of VELscopeTM for routine screening in the general population is limited. 
In a private practice setting, Huff et al found an increased rate of detection of oral epithelial 
dysplasia using VELscopeTM when compared to COE.130 However, this was conducted in parallel 
cohorts, not on the same patient base and the clinical characteristics of lesions discovered with 
VELscope were not discussed. It cannot be determined if the addition of VELscopeTM discovered 
new lesions or helped raise the suspicion of otherwise visible lesions. Truelove et al found five 
cases of dysplasia among a cohort of 620 patients which were not detected under COE.131 Both 
Huff and Truelove also incorporated a review period to allow the resolution of inflammatory 
lesions.130, 131 McNamara and colleagues however found the low specificity of VELscopeTM to be a 
concern arguing the use of VELscopeTM in routine screening would lead to a large number of over 
referrals.132 In addition to this, a case of moderate dysplasia of the lip did not display LAF 
reiterating previous concerns that in general practice, areas of dysplasia may be missed if clinicians 
become over-reliant on VELscopeTM. In this protocol, the authors did not consider VELscopeTM 
findings by re-examining areas with LAF clinically and proceeded to biopsy all areas with LAF. It 
is emphasised that LAF alone has little meaning without clinically re-examining the site to 
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eliminate inflammatory, pigmented or vascular lesions which may contribute to this 
phenomenon.127  
Laronde et al performed a large scale multi-centre and multi-operator study to evaluate what 
benefits fluorescence visualisation with VELscopeTM provides above that of a white light exam for 
routine screening of oral mucosal lesions.133 Lesions were categorised into high and low risk based 
on clinical characteristics and fluorescence positive or negative based on VELscopeTM findings. 
Common mucosal changes including amalgam tattoos, fordyces granules, vascularities and 
pigmentation due to skin colour were excluded. A three week review was incorporated to allow for 
healing of inflammatory lesions and patients were referred to oral medicine clinics as required.  
Lesion colour and texture were associated with LAF and those deemed high risk were more likely 
to be present at the three week review. The authors found that using fluorescence in addition to a 
clinical risk assessment provided the best prediction value for lesion persistence when compared to 
either screening modality on its own. In addition, the strength of models increased when the first 
25% of patients screened were removed which supports previous comments about the importance of 
clinician experience when interpreting VELscope findings. The importance of blanching was not 
assessed as a part of this study. 
In general, VELscopeTM can differentiate between normal mucosa and mucosal abnormalities; 
however, it is not highly specific in detecting OPMDs and as a result, gives rise to a high rate of 
false positives. The sensitivity varies among studies and this could be due to inter-operator 
variability in what constitutes LAF. It has been reported that there is a large spectrum of 
fluorescence and more definitive criteria in what constitutes LAF may be required before 
VELscopeTM can gain widespread use.124 Further, it has been suggested that a significant 
understanding of mucosal pathology is required to make correct clinical interpretations of 
VELscopeTM findings.127  This understanding may not be present in a general dental practice. Future 
research directions should evaluate what biological basis contributes to false positive and false 
negative findings. If the specificity of the device could be improved, there would be an increased 
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scope for the use of VELscopeTM in routine general practice. A new device called Sapphire 
PlusTM (DenMat Holdings LLC., CA, USA) appears to be a similar concept to VELscopeTM also 
utilising an extra-oral device with blue light induced autofluorescence however currently no 
literature is available its efficacy.41 
1.3.4.2 IdentafiTM  
IdentafiTM (Dental EZ, PA, USA), similarly to VELscopeTM uses in vivo autofluorescence to aid the 
dental practitioner in the detection of potentially malignant lesions.38 The IdentafiTM incorporates 
light sources of three different spectra within the one device. The first is a white light used to 
illuminate the oral cavity to enhance the conventional oral examination. As previously discussed, 
white light allowed for greater visibility than a traditional incandescent light source.35 The second 
light is a violet light at 405nm wavelength and uses the principles of autofluorescence similar to 
VELscopeTM. Previous studies have indicated a high sensitivity and specificity using this 
wavelength to discriminate between normal tissue and dysplasia or invasive carcinoma.134 The third 
light, a green-amber light at 545nm, is used to delineate abnormal vasculature of the underlying 
connective tissue. Vascularity has been shown to be a reliable indicator of angiogenesis in oral 
mucosal lesions.135 Increased vascularity has been observed to occur at an early stage in the 
dysplastic process with significant differences found between normal mucosa and mild dysplasia.135 
It is claimed that using the green-amber light can assist the clinician in visualising abnormal 
vasculature.136 Currently limited clinical data is available on the use of IdentafiTM.137 
While a larger trial is ongoing, Lane et al have released a sample of preliminary cases to illustrate 
lesion visualisation with IdentafiTM.136, 138 Lane et al observed that using the 405nm wavelength, 
areas of loss of fluorescence attributed to breakdown of stromal architecture is often larger than the 
clinically visible cancer.138 They also suggested that this is an indication of increased 
neovascularisation of the stroma.136 They proposed that these early findings indicate this technology 
could assist in determining surgical margins for excision of lesions.136 The green-amber light 
appears to emphasis keratinization of tissues and also highlights increased superficial vasculature.136  
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Sweeny et al evaluated the use of IdentafiTM in the follow up of 88 patients with a history of head 
and neck cancer.139 Both conventional examination and the use of the violet light was associated 
with a sensitivity of 50% however autofluorescence was associated with a decrease in specificity 
from 98% to 81%. The use of the green-amber light did not detect any dysplastic lesions providing 
a sensitivity of 0%. However, not all areas with loss of autofluorescence were biopsied and reasons 
why were not provided. It is possible that these areas had underlying epithelial dysplasia which was 
not apparent clinically. The authors did not specify what constitutes a positive finding, whether 
epithelial dysplasia, OSCCs or either. Included in the four positive lesions was one at the base of 
the tongue which can only be accessed via the use of a scope which would not normally be visible 
under conventional examination or using IdentafiTM. The study indicates that the use of IdentafiTM 
does not provide any assistance above that of COE. This data was based on clinicians with 
specialist level training and cannot be generalized to include dental practitioners. Evaluation of the 
device in general practice has not yet been undertaken and its benefits in routine oral screening are 
unknown. A new device termed DOE SETM (DentLight Inc., TX, USA) appears to be similar to 
IdentafiTM and also uses violet light for autofluorescence however currently no clinical trials are 
available on the device.42 
1.3.4.3 Future approaches to autofluorescence 
The previous literature indicates one of the significant downfalls of autofluorescence is the arbitrary 
nature of the technique and the significant inter-operator variability. To reduce this effect, a number 
of techniques have been devised which allow automated determination of the autofluorescence 
pattern to distinguish malignant or potentially malignant tissue from benign tissue.115 In the oral 
cavity, Roblyer et al utilised fluorescence with 405nm excitation and created threshold values based 
on a ratio of red to green autofluorescence.134 This ratio was used to determine a probability map 
assessing the risk of dysplasia in oral tissue with areas of greater than 50% risk being highlighted by 
the program. In the training set, this technique provided a sensitivity and specificity of 96%. In the 
validation set, these figures were 100% and 91% respectively. Future approaches to 
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autofluorescence should focus on computerised analysis using threshold values similar to this to 
remove the operator from the decision making process and allow for a less arbitrary decision 
making protocol. Similar concepts have been used to create an ‘optical biopsy’ using endoscopic 
techniques with autofluorescence in the surveillance of Barrett’s Oesophagus.115 This technique is 
associated with a high degree of sensitivity and specificity and allows diagnosis, rather than just 
detection of potentially malignant and malignant disorders of the oesophagus.140-142 Future research 
could look at creating a similar model to allow computerised differentiation between benign lesions, 
OPMDs and OSCCs. 
1.4 Conclusion 
It is well established that the majority of oral cancers are preceded by potentially malignant lesions 
and it is believed that the early detection of these lesions may assist in decreasing the mortality of 
oral cancer through early intervention. However these same lesions may seem benign, or may not 
be visible on visual inspection. In addition to this, currently it is impossible to predict which of 
these lesions will progress to malignancy. To assist the dental practitioner a number of aids have 
been developed to assist in the detection of these lesions as well help differentiate OPMDs from 
other benign lesions. ViziLiteTM and Microlux/DLTM were designed to allow easier visualization of 
lesions to assist in the detection of additional lesions but they do not effectively differentiate 
between benign lesions and OPMDs. The inability to consistently differentiate between benign and 
potentially malignant lesions also seems to be the downfall of both toluidine blue and VELscopeTM. 
Both of these are useful in delineating severe pathology and may have place in a specialist 
environment however due to their low specificity, currently they cannot be recommended for use in 
a general dental practice. With the current evidence available, a thorough COE under white light 
with a referral for biopsy when appropriate appears to be the most effective tool for the detection of 
OPMDs and oral malignancies.  
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1.5 Aims and hypothesis 
Currently, research indicates that VELscope can be of assistance in detecting dysplasia in clinical 
practice, however, there have been concerns raised regarding the number of false positives 
recorded. None of the publications have assessed the cellular and molecular reasons for false 
positive and false negative recordings. The present study aims to assess a decision making protocol 
for the use of VELscope in general clinical practice and also assess molecular characteristics of 
lesions and how they relate to visualisation under autofluorescence.  
The specific aims of this study are:  
1. To assess the efficacy of VELscope in detection of potentially malignant orders in general 
dental practice. 
2. To establish the impact of using VELscope in general practice on a clinician’s decision 
making ability with regards to referral of oral mucosal lesions. 
3. To create and assess a model incorporating both COE and VELscope for routine screening 
of patients for oral mucosal lesions. 
4. To determine characteristics of oral mucosal lesions at a molecular level which affect lesion 
visualization under autofluorescence. 
The hypotheses of this study are as follows: 
1. Incorporating VELscopeTM into routine dental examination using a decision making 
protocol will increase the detection of potentially malignant disorders however will also 
lead to an increase in the referral rate of benign oral mucosal lesions. 
2. Lesions which clinically display loss of autofluorescence under VELscopeTM will be 
associated with molecular characteristics indicating both oncogenesis and inflammation, 
compared to those with retained or diascopic fluorescence. 
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1.6 Significance of aims 
The study provides an insight into the clinical decision making ability of general dental practitioners 
with regards to referral of oral mucosal lesions and also how VELscope may be utilised to best 
assist in this process. The study aims to create a model for routine screening of potentially 
malignant disorders which has direct clinical implications for general dental practice. Also, the 
study will help elucidate molecular characteristics of lesions which produce false positives or false 
negatives which when correlated with clinical data will impact clinical decision making when using 
VELscope. 
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Chapter 2: Assessment of a decision making protocol to improve the 
efficacy of VELscopeTM in general dental practice: a prospective 
evaluation 
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2.1 Introduction 
Oral cancer ranks as the sixth most common malignancy worldwide with an estimated 263 900 new 
cases and 128 000 deaths in 2008 alone.8 Ninety percent of oral cancers are designated as oral 
squamous cell carcinomas (OSCCs).2 Despite an increase in our understanding of this disease, the 5 
year survival rate has remained at 50% for the past three decades.2  The poor prognosis for oral 
malignancies is largely related to delayed diagnosis with localised cancers having survival rates up 
to 83% compared to 32% once the tumour has metastasised.14, 143 Nearly half of all oral cancers 
present with an advanced stage tumour despite the fact that the oral cavity is an area easily 
visualized by the general medical or dental practitioner.9 Furthermore, a large percentage of OSCCs 
are preceded by visible changes of the oral mucosa.14 
The current standard for the detection of oral potentially malignant disorders (OPMDs) and OSCCs 
is visual examination.21 White, red or mixed red-white lesions with induration and fixation are 
suggestive of malignancy.21 However, 10-20.5% of the general population present with oral lesions 
of which the majority are benign in nature.144-146 A conventional oral examination (COE) is poor at 
differentiating benign lesions from OPMDs and malignancies.28 Further, histological evidence of 
dysplasia and microinvasive carcinoma has been found in clinically normal mucosa and these 
would evidently be missed by COE.29 With this in mind, new technologies have been developed 
which highlight OPMDs to assist clinicians in detecting and treating these lesions at an early stage.1, 
6, 115, 147
 
VELscopeTM (LED Medical Diagnostics Inc., Barnaby, Canada) is a non-invasive, handheld device 
designed to visualise early mucosal changes using the principles of tissue autofluorescence.39, 127 
VELscopeTM emits light in the 400-460nm spectrum which excites fluorophores intrinsic in the oral 
mucosa resulting in a pale green autofluorescence.107, 127 Abnormal tissue is associated with loss of 
autofluorescence (LAF) and appears dark in contrast to the surrounding tissue (see Figure 2.1).123 It 
is proposed that dysplasia is associated with alterations in the stromal architecture causing LAF.107 
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Lesions which completely blanch on pressure and return to a normal fluorescence pattern should be 
considered negative for LAF.127 This phenomenon is termed diascopic fluorescence.  
 
VELscopeTM is marketed to the general dental or medical practitioner for use as an adjunct to COE 
for the detection of oral mucosal abnormalities. Previous literature has found the device to be 
efficacious in identifying tumour margins which extend beyond the clinically visible margin of the 
lesion during excision of oral malignancies.123 It is also an effective tool for detecting dysplasia in 
patients with a history of OSCC.122 
VELscopeTM has been shown to be highly sensitive in the detection of severe dysplasia and OSCC; 
however its ability in detecting dysplasia at an early stage has been questioned with a number of 
false negatives noted.103, 127, 128, 132, 148 Authors have also relayed concerns that VELscopeTM tends to 
overestimate abnormalities with a number of benign lesions displaying LAF.103, 124, 125, 127, 128, 132, 148 
Farah et al stated the importance of clinical interpretation of lesions following VELscopeTM 
Figure 2.1: Lesion on lower lip with COE (a); same lesion with VELscopeTM 
displaying loss (dark area) and gain (lighter area) of fluorescence (b). 
Histopathological diagnosis was OSCC. Lesion showing poor visualisation with 
COE on lower lip (c); same lesion with VELscopeTM displaying loss of 
fluorescence (d). Histopathological diagnosis was actinic cheilitis. 
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examination rather than relying on LAF findings alone, and also highlighted the importance of 
diascopic fluorescence.127 Studies utilising VELscopeTM for routine screening have found increased 
rates of detection of epithelial dysplasia but with a substantial number of false positives.130-132 
While reviewing lesions with LAF may reduce false positives, none of the studies thus far have 
evaluated the significance of diascopic fluorescence in general practice.133 
The purpose of this study was to determine the value of VELscopeTM as an adjunct to COE for the 
general dental practitioner (GDP). The main aim was to assess a model for routine screening of 
patients for oral mucosal lesions incorporating both COE and VELscopeTM, and also to test a 
decision making protocol for patient referral. A secondary aim was to assess the sensitivity and 
specificity of COE, VELscopeTM and a combined examination for the detection of OPMDs and 
OSCCs in a general practice setting.  
2.2 Materials and methods 
Patient recruitment 
Patients presenting for general dental treatment at the University of Queensland, School of 
Dentistry were invited to participate in this study. Three-hundred and five consenting patients 
participated in the study between May 2012 and December 2013. The only exclusion criteria were 
patients under 18 years of age and those who were unwilling or unable to provide consent. All 
patients were examined in a prospective manner by a single general dental practitioner (author NB). 
The study was conducted according to Human Ethics Guidelines approved by the University of 
Queensland, School of Dentistry (project number 1204), and was designed in accordance with 
STARD guidelines.149 
Clinical protocol 
Patients were examined using a decision making protocol designed specifically for this study (see 
Figure 2.3).  
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Step 1. Background information: The age, sex, smoking history, alcohol use, mouthwash use and 
annual household income of all patients was recorded. 
Step 2.COE: COE was performed under incandescent operatory light and details regarding any oral 
mucosal lesions observed were noted. The location, size, ease of visibility and border distinctness of 
lesions were recorded, as previously described.127 All lesions were categorised by clinical 
description and then triaged into four clinical categories as previously described;127 homogeneous 
leukoplakia, non-homogeneous leukoplakia, lesions with lichenoid features or ‘Other’. A decision 
was made based on clinical presentation and features as to whether the lesion required a review or 
an OMS referral for further assessment. Non-homogeneous lesions were considered as suspicious 
for dysplasia and were marked for referral by the GDP. Lesions were photographed using a Canon 
A2200 camera. 
Step 3. VELscopeTM examination: Clinical examination was then repeated using VELscope VxTM 
and all lesions with LAF were assessed for diascopic fluorescence. Details regarding all lesions 
visible with VELscopeTM were recorded in the same manner as for COE. Lesions were then re-
photographed using a Canon A2200 camera with a VELscopeTM attachment. Lesions which 
displayed LAF with no blanching were recommended for referral to an OMS based on VELscopeTM 
findings alone. Lesions which displayed LAF and complete blanching were recommended for 
review based on VELscopeTM findings alone. Lesions with partial blanching were recommended for 
both review by the GDP and referral based on VELscopeTM findings at the initial examination 
alone. In addition to clinical assessment and referral decisions, answers to the following questions 
were recorded; 1) Did VELscopeTM detect any additional lesions?, 2) Did VELscopeTM enhance 
visibility?, 3) Did VELscopeTM change provisional/clinical diagnosis category?  
Step 4. Combined examination: Following VELscopeTM examination, sites with LAF were re-
assessed clinically at the same appointment. A further decision was then made for all lesions based 
on both clinical and VELscopeTM findings as to whether a review was required. Where LAF could 
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be accounted for on clinical grounds (eg: pigmentation or vascularity), no further follow up was 
required. Lesions which were suspicious for dysplasia based on COE were marked for referral to 
the OMS by the GDP. Lesions which were not suspicious for dysplasia based on COE but LAF 
could not be accounted for on clinical grounds were marked for review by the GDP. Patients 
requiring a review were reappointed after 14 days to allow for healing or resolution of lesions in 
case of trauma.  Photos were uploaded to secure Cloud storage (Dropbox; Dropbox Inc, San 
Francisco, CA, USA) and assessed by an oral medicine specialist (author CSF) with extensive 
experience in the use of VELscopeTM; this procedure is termed a telemedicine request.  
Step 5. Review appointment: At the review appointment (14 days after initial consultation), the 
combined examination was repeated. If lesions had healed, no further follow up was undertaken 
(Figure 2.2). Lesions which persisted and could not be documented as benign were marked for 
referral by the GDP (termed GDP referral) (Figure 2.3). Following this, the telemedicine request 
was reviewed by the GDP and patients were referred as determined by the OMS (author CSF). 
 
 
Figure 2.2: Geographic tongue on dorsal tongue (a); same 
lesion with VELscopeTM displaying loss of fluorescence (b); 
same area viewed with COE following 2 weeks with lesion 
having resolved (c); same area on follow up now shows 
normal fluorescence pattern with VELscopeTM (d). 
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Step 6. Referral appointment: All referred patients were assessed for oral mucosal lesions by the 
OMS (author CSF) and a scalpel biopsy was performed under local anaesthesia as indicated. For 
ethical reasons, only lesions that were clinically suspicious for malignancy or dysplasia, or those 
with VELscopeTM findings suggestive of malignancy or dysplasia were biopsied.  
Statistical analysis 
Data was entered into a database using Microsoft Access 2010 (Microsoft, Washington, USA) and 
exported to Microsoft Excel 2010 (Microsoft, Washington, USA) for subsequent analysis using R 
software (www.r-project.org). Associations between LAF categories, clinical categories, referral 
and healing patterns were calculated using Fisher’s exact test with corrections for multiple testing. 
A p value < 0.05 was considered significant. Post-hoc analysis was performed using pairwise 
Fisher’s exact tests. The sensitivity, specificity, positive and negative predicted value of COE, 
VELscopeTM examination alone, and combined examination at review were calculated. A decision 
to refer the patient was considered a positive outcome. A telemedicine request served as the soft 
gold standard with an indication that a consultation was required as a positive outcome; this is 
referred to as an OMS referral. Histopathological diagnosis served as the hard gold standard for 
biopsied lesions. In addition, analysis of the decision making protocol was carried out regarding 
how often VELscopeTM enhanced detection, how often it detected new lesions, or changed 
provisional clinical diagnosis. 
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Homogenous 
leukoplakia suggestive 
of keratosis, lichenoid 
lesions or “Other” not 
suspicious for dysplasia 
were marked as 
requiring no further 
follow-up.  
Homogenous 
leukoplakia with no 
suggestive aetiology, or 
“Other” lesions which 
could not be discounted 
as benign were either 
marked for review or 
referral by the GDP.  
Non-homogenous 
lesions were considered 
suspicious for dysplasia 
and marked for referral 
based on COE. 
  
Age, sex, 
smoking hx, 
alcohol hx, 
mouthwash hx 
and household 
income were 
recorded. 
  
Based on VELscope 
alone, LAF with 
partial or no 
blanching were 
considered 
suspicious for 
dysplasia and marked 
for referral.  
Lesions with LAF 
with complete 
blanching were 
considered benign 
and marked for 
review.  
Lesions with no LAF 
were marked as not 
requiring any follow-
up. 
  
Lesions with 
LAF were 
reviewed under 
COE to assess if 
there was any 
clinical 
explanation for 
LAF (etc 
pigmentation, 
vascularity, 
traumatic 
inflammation). 
  
Lesions which on combined 
findings were considered 
benign or where LAF could be 
accounted for on clinical 
grounds, were marked by the 
GDP as no follow-up required.  
Lesions which based on COE 
findings were suspicious for 
dysplasia were referred to the 
OMS.  
Lesions where LAF could not 
be accounted for on clinical 
grounds and were not 
suspicious for dysplasia with 
COE were marked for review to 
assess for healing and possibly 
traumatic causes. 
  
If at the review 
appointment the lesion 
had healed or could be 
discounted as benign 
on clinical grounds 
then the lesion was 
marked as no follow-
up required by the 
GDP.  
Lesions which had not 
healed by the review 
appointment and 
where LAF could not 
be accounted for on 
clinical grounds were 
noted as requiring a 
referral by the GDP.  
  
Background 
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COE 
  
VELscope 
exam   
Combined 
exam   
Lesion 
present 
  
Review by 
GDP 
  
No review/ 
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required 
  
Refer to 
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Lesion 
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review 
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present on 
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Refer to 
OMS 
  
No  
referral 
  
No lesions 
present – no 
further follow-up 
  
Review 
telemedicine 
request 
  
The telemedicine 
request was 
reviewed by the 
GDP, and the 
patient was referred 
as determined by 
the OMS. 
Figure 2.3: Summary of decision making protocol. 
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2.3 Results 
A total of 305 patients were examined using the decision making protocol. Patient demographics 
are summarised in Table 2.1. 
Table 2.1: Patient demographics (n = 305) 
 
Table 2.2: Lesion location (n = 222) 
Lesion location Frequency, n (%) 
 Buccal mucosa 80 (36.0%) 
External lip  36 (16.2%) 
Hard palate 33 (14.9%) 
Tongue 23 (10.4%) 
Alveolar ridge 15 (6.8%) 
Retromolar pad 9 (4.0%) 
Labial mucosa 9 (4.0%) 
Vestibule 7 (3.2%) 
Floor of mouth 5 (2.2%) 
Gingiva 4 (1.8%) 
Soft palate 1 (0.5%) 
 
One hundred and forty-six patients (47.9%) presented with at least one oral mucosal lesion and a 
total of 222 lesions were detected. The majority of lesions occurred on the buccal mucosa followed 
by the external lip (Table 2.2). COE revealed 161 lesions of which 91 displayed LAF. An additional 
61 lesions were discovered using VELscopeTM, 58 of which displayed LAF while 3 displayed gain 
in fluorescence with no LAF (Figure 2.4). Homogeneous leukoplakia was the most common 
Characteristic Male (n = 147) Female (n = 158) Total (n = 305) 
Age, mean ± SD, y 49.3 ± 16.0 50.1 ± 13.8 49.7 ± 14.9 
Current/past smokers, n 77 (52.4%) 68 (43.0%) 145 (47.5%) 
Lifetime tobacco exposure, mean 
(pack years) ± SEM 16.6 ± 2.2 15.0 ± 2.0 15.9 ± 1.3 
Current/past alcohol consumer, n 116 (78.9%) 96 (60.8%) 212 (69.5%) 
Current smoker & alcohol 
consumer, n 
23 (15.6%) 18 (11.4%) 41 (13.4%) 
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description of clinically visible lesions while “Other” lesions presented the most common clinical 
category (Table 2.3 and Table 2.5). Follow-up of lesions is summarised in Figure 2.5. There was no 
significant association between the presence of an oral mucosal lesion and tobacco use, alcohol use, 
mouthwash use, household income or gender, however patients above the age of 45 were 
significantly more likely to have an oral mucosal lesion compared to those equal to or below 45 
years of age (p=0.044) (Table 2.4).  
Table 2.3: Lesion description on COE (n = 161) 
 
 
 
 
 
VELscopeTM enhanced detection of lesions in 61 patients (20.0%) and detected additional lesions in 
49 patients (16.0%). VELscopeTM also changed the provisional diagnosis in 39 patients (12.8 %). 
Among 161 lesions detected with COE, VELscopeTM increased visibility of 16 (9.9%) lesions, 
while 7 (4.3%) were more easily visible under COE. Border visibility was also increased in 21 
(13.0%) lesions with VELscopeTM while COE provided greater border distinctness in 7 (4.3%) 
lesions. 
Lesion description Frequency, n (%) 
Homogeneous 55 (34.2%) 
Pigmented 21 (13.0%) 
Linea alba 15 (9.3%) 
Vascular 14 (8.7%) 
Traumatic 11 (6.8%) 
Ulcer 11 (6.8%) 
Non-homogeneous 8 (5.0%) 
Petechia 2 (1.3%) 
Other 24 (14.9%) 
  
305 patients 
  
222 lesions 
  
161 COE visible 
  
61 COE            
non-visible 
  
58 LAF 
  
3 gain in 
fluorescence   
91 LAF 
  
57 no LAF 
  
13 gain in 
fluorescence 
Figure 2.4: Lesion visualisation under COE and VELscopeTM. 
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Table 2.4: Association between clinical and demographic parameters, and LAF status of lesions     
(n = 222) 
Variable No LAF LAF  
Gender   p=0.57 
 Male 41 73  
 Female 32 76  
Age   p=0.35 
 ≤45 years 26 34  
 >45 years 47 115  
Annual household income 
($AUD) (n = 217)   p=0.57 
 < $20,000 17 26  
 $20 000 – 40 000 19 46  
 $40 000 – 60 000 11 32  
 $60 000 – 80 000 16 21  
 $80 000 – 100 000 7 13  
 > $100 000 1 8  
Smoking   p=0.57 
 Never 38 72  
 Current or past 34 77  
Alcohol use   p=0.57 
 Never 30 49  
 Current or Past 43 100  
Mouthwash use   p=0.57 
 Never 43 101  
 Current or past 30 48  
Lesion size    p=0.35 
 ≤200mm2 68 2  
 >200mm2 81 10  
 
Of the 222 lesions detected, 71 were reappointed for a review while 15 were referred to an oral 
medicine specialist without a review. Thirteen patients were referred to the OMS at the initial 
examination for lesions with clinical indications that they were long standing, or where the patient 
refused review for logistical reasons, and a referral was warranted on initial examination. No 
associations were found between patient demographics or lesion size with LAF (Table 2.4). There 
was no significant association between rates of healing and LAF category (p=0.12) or clinical 
category (p=0.08) (Table 2.6) although lesions with LAF and no blanching tended to show a higher 
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rate of healing on review. A total of 23 lesions in 18 patients were referred. Ten biopsies were 
performed and are summarised in Table 2.7. One patient opted to undertake a biopsy privately for 
logistical reasons. Under COE, 13 lesions were marked for referral by the GDP while an additional 
9 lesions were marked for referral following the decision making protocol. Among these, one case 
was actinic cheilitis with mild dysplasia. One case of actinic cheilitis with mild dysplasia was not 
marked for referral by the GDP but was referred following an OMS telemedicine request. A 
telemedicine request with photographs was available for 152 lesions including all lesions which 
were referred. A telemedicine request based on clinical description alone was available for the 
remaining 70 lesions. 
Table 2.5: Fluorescence characteristics as a proportion of clinical lesion category as determined by 
the GDP (n, %) 
 
A significant association was found between clinical category and LAF (p<0.001). Homogeneous 
lesions were significantly more likely to present with no LAF (p<0.001) while non-homogeneous 
lesions had an increased likelihood of presenting with LAF although this did not reach significance 
(p=0.055). An association was found between clinical category and GDP referral (p<0.001) and 
OMS referral (p<0.001). In both cases, non-homogeneous lesions were significantly more likely to 
require referral (p<0.001) while lesions categorised as “Other” were unlikely to require referral 
(p<0.001). LAF category was associated with both GDP referral (p<0.001) and OMS referral 
(p<0.004). Lesions displaying LAF with partial blanching were associated with a higher likelihood 
Clinical category No LAF 
LAF with 
complete 
blanching 
LAF with partial 
blanching 
LAF with no 
blanching Total 
Homogeneous 41 (74.5%) 8 (14.5%) 6 (11.0%) 0 (0%) 55 (100%) 
Non-
Homogeneous 0 (0%) 1 (12.5%) 4 (50.0%) 3 (37.5%) 8 (100%) 
Lichenoid 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Other 29 (29.6%) 16 (16.3%) 6 (6.1%) 47 (48.0%) 98 (100%) 
Not seen 
clinically 3 (4.9%) 17 (27.9%) 14 (23.0%) 27 (44.2%) 61 (100%) 
Total 73 (32.9%) 42 (18.9%) 30 (13.5%) 77 (34.7%) 222 (100%) 
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of referral by both GDP (p<0.001) and OMS (p<0.001) although other fluorescence categories did 
not show any significant associations. Lesion site was also significantly associated with referral by 
the GDP (p<0.001) and the OMS (p<0.001) with lesions on the external lip presenting with a 
significantly increased likelihood of requiring referral by both practitioners (p<0.001). 
 Table 2.6: Review and referral patterns based on LAF category as determined by the GDP 
 
The sensitivity and specificity for COE and VELscopeTM are summarised in Table 2.8. The 
sensitivity and specificity for a combined examination was calculated using the findings of COE 
and VELscopeTM on review if available. For patients where lesions were considered benign at the 
initial examination and no review was conducted, or a referral was made without review, combined 
COE and LAF findings at the initial appointment were used. Patients who did not return for 
scheduled reviews were excluded from the combined findings leaving 210 lesions. The sensitivity 
of COE, when compared with the soft gold standard was 44.0% while the sensitivity of 
VELscopeTM examination was 64.0%. However, the sensitivity for a combined examination was 
greater than either examination alone at 73.9%. This was associated with only a small drop in 
specificity from 99.0% for COE to 97.9% for combined findings. 
 
 
LAF category Total No follow up 
required 
Reviewed Changes on 
review 
GDP referral OMS referral 
No LAF 73 56 (76.7%) 11 (15.1%) 5 (6.8%) 3 (4.1%) 5 (6.8%) 
LAF - complete 
blanching 
42 27 (64.3%) 11 (26.2%) 6 (14.3%) 3 (7.1%) 4 (9.5%) 
LAF - partial 
blanching 
30 8 (26.6%) 14 (46.7%) 8 (26.7%) 10 (33.3%) 11 (36.7%) 
LAF - no blanching 77 43 (55.8%) 26 (33.8%) 21 (27.3%) 5 (6.5%) 5 (6.5%) 
Total 222 134 (60.4%) 79 (35.6%) 40 (18.0%) 21 (9.5%) 25 (11.3%) 
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Table 2.7: Histopathological diagnoses and clinical characteristics as determined by GDP of lesions 
which underwent biopsy (n = 10) 
Lesion 
ID Location COE category LAF category 
COE 
referral 
GDP 
referral Histopathology 
124 Lower 
external lip Non homogeneous 
Partial 
blanching No No 
Actinic cheilits with mild 
dysplasia 
127 Buccal 
mucosa 
Non homogeneous Partial blanching Yes Yes Lichenoid reaction 
193 Lower 
external lip Homogeneous 
Partial 
blanching Yes Yes 
Actinic cheilits with mild 
dysplasia 
107 Lower 
external lip Not seen clinically 
Partial 
blanching No No Actinic cheilitis 
112 Hard palate Homogeneous Partial blanching Yes Yes Papillary hyperplasia 
170 Lower 
external lip Homogeneous 
Complete 
blanching Yes Yes Actinic cheilitis 
171 Lower 
external lip Non homogeneous 
Partial 
blanching Yes Yes OSCC 
175 Lower 
external lip Not seen clinically 
Complete 
blanching No Yes 
Actinic cheilits with mild 
dysplasia 
197 Lower 
external lip Non homogeneous 
Complete 
blanching Yes Yes 
Actinic cheilits with mild 
dysplasia 
219 Lower 
external lip Non homogeneous No blanching Yes Yes 
Moderately dysplastic 
actinic cheilitis 
 
40 
  
222 lesions 
  
149 LAF 
  
73 No LAF  
  
3 referred 
  
14 review booked 
  
56 benign 
  
4 benign 
  
2 referred 
  
5 healed 
  
3 FTA 
  
2 consult 
  
80 benign 
  
12 referred 
  
57 review booked 
  
10 benign 
  
6 referred 
  
9 FTA 
  
32 healed 
  
5 biopsy 
  
1 consult 
  
5 biopsy 
  
4 consult 
  
3 FTA 
  
1 FTA 
  
2 consult 
FTA = Failure to attend. These 
patients were lost to follow up. 
  
146 patients – lesion present 
  
159 patients – no lesion 
  
305 patients 
Figure 2.5: Results of screening displaying follow-up and outcomes of lesions discovered with the use of the decision making protocol. 
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2.4 Discussion 
It is commonly believed that early diagnosis of OPMDs and active intervention may prevent the 
progression of disease to malignancy and provides the highest standard of care.13, 14 In a recent 
study, we have shown that one in five people present with an oral mucosal lesion.146 However it is 
often difficult to differentiate benign lesions from OPMDs with COE.28 For this reason, a number of 
adjunctive optical techniques have been devised to assist the general practitioner to detect oral 
mucosal lesions and also to differentiate benign lesions from OPMDs. Of these, autofluorescence 
devices appear to show promise in this regard. Among devices incorporating autofluorescence for 
oral mucosal screening, VELscopeTM   enjoys the greatest amount of supporting literature. 
The majority of research associated with VELscopeTM assesses its diagnostic potential in a 
specialist environment.103, 120, 124-128 The consensus appears to be that while VELscopeTM is 
efficacious at highlighting dysplasia, using the device alone overestimates abnormalities. Reported 
sensitivities and specificities for the device in specialist practice range from 30 to 100% and 15 to 
81% respectively.115 These values however, cannot be extrapolated to general dental practice where 
the prevalence of oral mucosal lesions is significantly lower than a secondary referral centre. 
Furthermore, previous studies have focused on the diagnostic accuracy of VELscopeTM and its 
ability to detect dysplasia. However, the device is intended to be used as an adjunct to a clinical 
examination and not as a stand-alone diagnostic tool.39 The role of a general practitioner is not 
necessarily to diagnose dysplasia, but to make appropriate clinical decisions and referrals to a 
specialist centre where the patient can be diagnosed and managed appropriately. This means 
referring lesions that appear suspicious, but also knowing when not to refer, to maintain the highest 
standard of patient care. Therefore in general practice, while assessing the ability to detect dysplasia 
can be one outcome measure, the ultimate aim of an oral mucosal examination should not be to 
detect dysplasia, but to detect and appropriately refer oral mucosal abnormalities. 
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Given the low specificity associated with the use of VELscopeTM, there is concern that this would 
result in a significant increase in the number of specialist referrals which may lead to patient harm 
through unnecessary stress, and wasted time and financial costs. This was the concern expressed by 
McNamara et al who found that a number of benign lesions displayed LAF.132 This is in agreement 
with findings from the current study, in that a number of lesions which were clinically benign 
displayed LAF. We found that clinical interpretation is extremely important when utilising 
VELscopeTM as relying on LAF findings alone is unreliable. Pigmented lesions, vascular lesions 
and inflammatory lesions in particular may confound the operator as they also present with LAF.127, 
133
  A common finding in this study was the presence of  areas of LAF under dentures in clinically 
normal tissue displaying chronic inflammation.150 In contrast to our protocol, McNamara et al 
biopsied all lesions with LAF which did not resolve.132 As can be seen in the current study, this is 
unwarranted. 
With this in mind, similar to the present study, Laronde et al introduced a three week review to 
allow for resolution of inflammatory lesions.133 Lesion colour and texture were found to be 
associated with LAF with red or mixed red/white lesions as well as pigmented lesions, more likely 
to demonstrate LAF compared to white lesions. Whether the lesion was homogeneous or non-
homogeneous did not show any significant associations.133 This is in contrast to the present study, 
where a non-homogeneous appearance was associated with LAF as well as an increased likelihood 
of referral. We have previously shown that a non-homogeneous appearance is associated with oral 
epithelial dysplasia, and so it would be assumed that non-homogeneous lesions would also be 
associated with LAF.23 
Laronde et al also found that lesion persistence was best predicted using a combination of clinical 
examination and VELscopeTM findings than with either screening modality alone,133 a finding 
echoed  in the current study where the combined examination provided a more accurate assessment. 
In the present study, using the decision making protocol an additional five patients were identified 
for referral beyond COE, of which one patient proved to have mild dysplasia. While there was a 
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small drop associated in specificity of referrable lesions from 99.0% to 97.9%, this was not as 
significant as previously reported when diagnosis of dysplasia was used as an outcome measure.127, 
132
 Compared to the specificity of VELscopeTM alone, the combined protocol removed a large 
portion of over-referrals. The use of the decision making protocol is also associated with an increase 
in sensitivity from 44.0% to 73.9%, while the sensitivity of VELscopeTM was 64.0%. The 
importance of COE cannot be understated as VELscopeTM itself may not detect all significant 
lesions as it has been found that not all cases of dysplasia display LAF.127 
Table 2.8: Sensitivity and specificity of COE, VELscopeTM and combined examination following 
the decision making protocol. OMS referral used as soft gold standard. (%, 95% CI) 
 COE VELscope Combined 
Sensitivity 44.0% (24.4 – 65.1%) 64.0% (42.5 – 82.0%) 73.9% (51.6 – 89.7%) 
Specificity 99.0% (96.4 – 99.9%) 54.3% (47.1 – 61.4%) 97.9% (94.6 – 99.4%) 
PPV 84.6% (54.4 – 97.6%) 15.1% (8.9 – 23.4%) 81.0% (58.1 – 94.4%) 
NPV 93.3% (89.0 – 96.3%) 92.2% (85.8 – 96.4%) 96.8% (93.2 – 98.8%) 
 
While previous studies have stated the importance of diascopic fluorescence,127 the significance of 
blanching has not been assessed in general practice. In the present study, lesions which partially 
blanched were associated with the highest rate of referrals. Among reviewed lesions, those with 
LAF and no blanching tended to show the highest rates of healing although this did not reach 
significance. This highlights the importance of reviewing patients with LAF and not acting on 
initial findings. Epithelial dysplasia can be associated with inflammation and changes in underlying 
vasculature which can contribute to the problem of partial blanching.151 The higher rate of healing 
among reviewed lesions with no blanching may be due to the presence of extravasated haemoglobin 
in acute traumatic events which are a frequent occurrence in the oral environment. Accurate 
blanching can be difficult to perform and is highly dependent on operator interpretation; however it 
forms an essential part of assessment of lesions using autofluorescence. Blanching was more easily 
performed using the back of a periodontal or sickle probe rather than the back of a mirror 
particularly with smaller lesions and in difficult to access areas.  
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One of the limitations of this study is that it is a single centre study performed in a uniform 
population. All cases of dysplasia found in this screening study were located on the lower lip which 
is not surprising given that the highest incidence of OSCCs in this population occurs on the lower 
lip due to high levels of sun exposure.152, 153 In other populations, where other factors such as the 
use of betel quid play a more prominent role in the development of OSCCs, results may vary and 
LAF patterns of lesions such as submucous fibrosis need to be taken into account. Nonetheless, the 
results of our study utilising the decision making protocol are generalizable to other populations. 
It is possible that significant oral mucosal lesions were missed since not all patients were seen by a 
specialist practitioner. However, this more closely simulates a real world environment where only 
patients with lesions deemed to be significant by the primary clinician are seen in a secondary 
referral centre. Further testing of this decision making protocol with multiple practitioners in 
multiple centres is required to confirm its applicability and generalizability. 
2.5 Conclusion 
Using VELscopeTM alone to screen patients in routine general dental practice over-estimates the 
burden of significant oral mucosal abnormalities and may lead to over-referral. Using the decision 
making protocol presented in this study, with particular emphasis on careful clinical interpretation 
and reviewing lesions where appropriate, can result in a decrease in the number of unnecessary 
referrals which may occur if relying on LAF alone. In addition, VELscopeTM may aid in the 
detection of dysplasia which may not be identified by COE alone. Future research should focus on 
large scale multi-centre trials to assess what additional benefits this technology brings to COE. 
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3.1 Introduction 
Oral and oropharyngeal cancer is the sixth most common malignancy worldwide and are being 
diagnosed at an increasing rate.2 It is estimated that in 2008, 263,900 new cases of oral cancer were 
diagnosed worldwide contributing to 128,000 deaths.8 Oral squamous cell carcinomas (OSCCs) 
make up the large majority of oral cancers and are most often attributed to smoking, alcohol and use 
of betel quid.2-5 Despite advances in knowledge on prevention, diagnosis and treatment of these 
cancers, the 5 year survival rate has remained at 50% for the last 3 decades.2 A large reason for this 
is the delayed diagnosis of oral cancers with more advanced tumours having a significantly worse 
prognosis.9-11, 143 This is despite the oral cavity being an area easily accessible to the medical or 
dental practitioner.  
To improve outcomes, a number of clinical aids have been developed which utilise the properties of 
vital staining, chemiluminescence, reflectance or autofluorescence to help detect not only malignant 
lesions but also epithelial abnormalities which may proceed to malignancy.1, 6, 21, 115 Many of these 
have evolved from technologies used in the detection of cervical dysplasia due to the similarity in 
structure of cervical and oral mucosa. Autofluorescence is one such technique which has been 
commercialised for use in the oral cavity.118  
Autofluorescence occurs due to excitation of endogenous fluorophores in the oral mucosa by using 
light within specific spectra causing tissues to display autofluorescence.106 In the oral cavity, 
autofluorescence is largely due to nicotinamide adenine dinucleotide reduced form (NADH) and 
flavin adenine dinucleotide (FAD) within the epithelium and cross links in collagen within the 
stroma.107 Oral mucosal abnormalities are associated with a loss of autofluorescence (LAF).  
Several studies have assessed both in vitro and in vivo the fluorescent properties of cervical 
epithelium and its ability to differentiate cervical dysplasia from normal mucosa.107, 110, 112, 154 
Pavlova and colleagues found that cervical dysplasia has a significant loss of stromal fluorescence 
relative to normal mucosa when excited with light in the UV spectrum. Drezek et al found that there 
was increased epithelial fluorescence in cervical dysplasia but a decrease in autofluorescence from 
48 
the stroma at UV excitation.110 Using a light source with a 460nm wavelength, results similar to that  
seen by Pavlova et al were noted, with loss of stromal autofluorescence and no significant changes 
in epithelial fluorescence.110 The oral mucosa displays similar properties to cervical mucosa with 
dysplasia having loss of stromal autofluorescence at the 488nm wavelength with a slight gain in 
autofluorescence in the epithelial layer.107, 113 
VELscopeTM (LED Medical Diagnostics Inc, Barnaby, Canada) is a simple, non-invasive handheld 
device marketed for the detection of malignant and potentially malignant lesions of the oral mucosa 
in a clinical environment.127, 155 VELscopeTM utilises blue excitation light within the 400-460nm 
spectrum which causes an apple green fluorescence of normal mucosa.127 Abnormal tissue is 
associated with LAF and appears darker in contrast to the surrounding tissue. While the sensitivity 
of VELscopeTM for severe dysplasia, carcinoma-in-situ and OSCC is relatively high120, concerns 
have been raised as early stages of dysplasia can be overlooked.103, 127, 128 Furthermore, studies have 
reported a high number of false positives indicating low specificity of the device.103, 125, 127, 128, 132 
The false positives appear to be largely caused by benign inflammatory conditions.127 In many 
cases, inflammatory lesions may display a property called diascopic fluorescence where the lesion 
blanches when pressure is applied and retains fluorescence much like normal mucosa however this 
is often difficult to achieve and does not eliminate false positives entirely.127, 156 In addition to this, 
cases of dysplasia and OSCC may also display diascopic fluorescence.127 In vitro studies support 
the notion that inflammation can be attributed with LAF within both the stromal and epithelial 
layers.107, 113 Previous literature shows that inflammation can cause greater LAF than dysplasia 
since this occurs at both the stromal and epithelial layers as opposed to being limited to the stromal 
layer in dysplasia.113  
While the fluorophores and architecture of the oral mucosa responsible for LAF are well 
established, there is limited knowledge of the molecular characteristics of lesions and how this 
relates to LAF in a clinical environment. By assessing this, it is envisaged that elucidation of the 
underlying causes for the reported false positive and false negative findings can be undertaken 
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allowing for more accurate clinical decision making using VELscopeTM. The aim of this study was 
to assess the properties of oral mucosal lesions with regards to gene expression and their relation to 
fluorescence properties when visualised under direct tissue autofluorescence to identify potential 
candidate genes which may be involved in LAF. Lesions with histopathological diagnoses of 
OSCC, dysplasia, lichenoid inflammation or benign keratosis/hyperplasia with clinical notes 
regarding fluorescent characteristics were included for comparison in this study. The study utilised 
Next Generation Sequencing (NGS) RNA-Seq for analysis of differential gene expression.  
3.2 Materials and methods 
Patient and tissue selection 
Archival material from patients referred to an oral medicine specialist (CSF) for investigation of a 
suspicious oral mucosal lesions between 2008 – 2013 were manually searched and cross matched 
across databases to obtain fresh frozen tissue samples with matched clinical data regarding 
fluorescence characteristics with VELscopeTM. All specimens had been preserved in RNAlater® 
(Applied Biosystems) and stored at -80ºC. Clinical and histopathological details along with 
fluorescence characteristics were obtained from clinical records. Specimens were categorized into 
four groups; OSCCs, dysplasia, lichenoid lesions and keratosis/hyperplasia. These were further 
subdivided into three groups; lesions without LAF, lesions with LAF and no blanching, and lesions 
with LAF with partial or complete blanching. Histopathological diagnosis was performed by a head 
and neck pathologist independent of the study and confirmed by an oral pathologist (CSF) blinded 
to the original biopsy result. Where there was disagreement, the oral pathologist’s (CSF) diagnosis 
was used. 
RNA-Seq library preparation and Next Generation Sequencing 
Total RNA was extracted using the AllPrep DNA/RNA/miRNA Universal kit (Qiagen, 
Netherlands) and the quality of RNA was assessed using a NanoDrop ND1000 spectrophotometer. 
Cytoplasmic, mitochondrial and ribosomal RNA was removed from the total RNA using 
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RiboMinus™ Eukaryote System v2 / Low Input RiboMinus™ Eukaryote System v2 (Life 
Technologies, USA). Double stranded cDNA was synthesised, and libraries prepared using Ion 
Total RNA-Seq Kit v2 (Ion Torrent) as per manufacturer’s instructions. Libraries were barcoded 
with adaptors from Ion Xpress™ RNA-Seq Barcode 1-16 Kit (Ion Torrent) and pooled libraries 
were created. Samples were diluted to 7pM and templated Ion sphere particles (ISPs) were prepared 
using an Ion P1 200 Template kit v3 (ThermoFisher Scientific, USA) on a OneTouch2 and enriched 
using a OneTouchES system. The templated ISPs were then loaded onto Ion P1v2 sequencing chips 
as described by the manufacturer and sequenced for 500 flows on a Proton sequencer 
(ThermoFisher Scientific, USA) using an Ion P1 sequencing 200 Kit v3, resulting in 70-90 million 
reads per chip after quality filtering to remove low quality bases from the 3’ end. The reads were 
split according to barcodes using Torrent Suite 4.2. 
Next Generation Sequencing Bioinformatic Analysis 
Raw reads from the sequencing libraries were quality checked with fastQC tool for sequence quality 
and GC content. The raw reads were mapped against the hg19 whole human genome as a reference 
using Burrows-Wheeler Aligner (BWA).157 Mapping statistics and quality were generated using 
RNA- SeQC v1.1.7.  
Differential expression analysis 
Hierarchical clustering was performed using a matrix of euclidean distances calculated from the 
mapped read counts for the 30 most highly expressed genes following variance-stabilizing 
transformation (VST). Principal Component Analysis (PCA) was performed using VST normalized 
data with the mixOmics package to assess for variance among samples; for subsequent analysis data 
from the first and second dimension were used.158 Limma was used to apply a linear model  to 
voom-transformed read counts after which t-tests were performed to identify the most significantly 
differentially expressed genes between categories following PCA.  
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Sparse partial least square discriminant analysis (sPLS-DA) was employed to identify expressed 
genes which differentiate histological diagnosis within each fluorescence category, and also 
different fluorescence patterns within each histological category.159 sPLS-DA was run with two 
components and one hundred genes per component to separate each group. Cross-validation was 
performed by re-running the sPLS-DA excluding one sample in each run to identify genes that were 
selected in at least 70% of the runs in either of the two components. Expression profiles of these 
genes were plotted for further exploration. Using this, a potential gene list was created and the mean 
and log fold change for the corresponding gene was calculated using the VST normalized data. A 
mean log Fold change of 0.75 was used as a cut-off point to find candidate genes. 
Lesions were grouped into histological categories and subdivided by fluorescent characteristics and 
again assessed for differential gene expression. Once a list of potential candidate genes was 
established, these were manually investigated through searching the NCBI gene database, 
GeneCards and PubMed to obtain a list of candidate genes based on biological relevance.160-162 
These were confirmed based on established relationships with head and neck malignancies, other 
malignancies, inflammation, angiogenesis or cell cycle regulation. 
3.3 Results 
Patient and sample details 
A total of forty-three biopsy samples from forty-one patients were used in the study. A biological 
replicate of one sample in the keratosis displaying LAF with blanching group was created during 
library preparation leading to forty-four samples in total. Patient details are summarised in Table 
3.1. Sample groups, including histological diagnoses and LAF details are summarised in Table 3.2. 
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Table 3.1: Summary of patient demographics (n = 41) 
 
Table 3.2: Sample sizes for experimental groups 
Histopathological diagnosis LAF with no blanching LAF with blanching No LAF 
OSCC 2 2 0 
Dysplasia 5 5 5 
Lichenoid lesions 4 5 1 
Benign keratosis/hyperplasia 4 6 5 
 
Mapping statistics and quality 
The quality profile of all libraries were within normal limits with an average quality score per read 
of approximately 24 (Phred score) dropping towards the end of the reads in some cases. A 
consistent GC content was observed along the reads. An average of 60% intragenic mapping was 
observed as well as an average of approximately 16,000 genes detected per library. Forty-one 
libraries were mapped to a high degree with mapping percentage between 79.6 – 94.1% while three 
libraries were only mapped at a rate between 52.2 – 61.6% (see Appendix A for summary of 
mapping statistics). Samples displayed consistent distribution of raw read counts although one 
separate divergent profile was observed.  
 
 
Characteristic Male (n = 16) Female (n = 25) Total (n = 41) 
Age at biopsy, mean ± SD, y 57.5 ± 14.0 58.6 ± 11.5 58.1 ± 12.4 
Current/past smokers, n 10 (n = 16) 14 (n = 25) 24 (n = 41) 
Lifetime tobacco exposure, mean 
(pack years) ± SEM 
27.0 ± 4.7 
(n = 10) 
22.4 ± 5.5 
(n = 11) 
24.6 ± 3.6 
(n= 21) 
Current/past alcohol consumer, n 13 (n = 16) 17 (n = 24) 30 (n = 40) 
Current smoker & alcohol 
consumer, n 
9 (n = 16) 8 (n = 24) 17 (n = 40) 
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Unsupervised differential expression analysis 
Hierarchical clustering with the thirty most highly expressed genes did not show any apparently 
clustering between samples (see Figure 3.1). Using PCA, when grouped by histological diagnosis, 
OSCCs and lichenoid samples tended to cluster together while keratosis and dysplasia tended to 
cluster together (see Figure 3.2). The first dimension explained 12% of the variability in the data 
while the first and second dimensions together explained just over 20% of the variability in the data; 
these dimensions were represented in the PCA plot.  
No clear separation was found between LAF patterns when histological diagnoses were combined 
(see Figure 3.3). Significantly differentially expressed genes were only found between the LAF 
with blanching groups and no LAF (see Table 3.3)  and of these only CEBPA and PCM1 were 
considered relevant. When assessing differences between LAF patterns within each histological 
diagnosis, again no clear separation was observed using PCA (see Appendix B).  
Figure 3.1: Hierarchical clustering of all libraries using the 30 most highly 
expressed genes after VST normalization 
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Figure 3.2: PCA result for the first two dimensions from VST transformed read 
counts of all samples based on histology. 
Figure 3.3: PCA result for the first two dimensions from VST transformed read 
counts of all samples based on LAF pattern. 
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Table 3.3: Differentially expressed genes for LAF with Blanching vs No LAF for all samples from 
PCA (positive logFC indicates greater expression in LAF with Blanching and vice versa) 
Gene ID HGNC symbol Average expression logFC Adjusted P value 
1050 CEBPA 5.27 -1.25 0.05 
64118 DUS1L 5.10 -0.88 0.03 
115939 TSR3 3.52 -0.71 0.03 
5108 PCM1 5.98 0.57 0.03 
 
To assess for differences in gene expression regardless of blanching, and also to reduce the impact 
of histology in differential gene expression, LAF with and without blanching were combined and 
analyses were repeated after exclusion of OSCC and lichenoid samples. When OSCC samples were 
excluded, LAF and no LAF could be separated based on a diagonal line (see Figure 3.4). Twenty-
four differentially expressed genes were identified of which five were considered biologically 
relevant (see Table 3.4). The analysis was repeated including only keratosis and dysplasia samples 
but these did not show any clustering based on LAF (see Figure 3.5). Six differentially expressed 
genes were identified of which three were considered candidate genes (see Table 3.5). A full list of 
differentially expressed genes are available in Appendix C. 
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Figure 3.4: PCA result for the first two dimensions from VST transformed read 
counts of all samples excluding OSCC based on LAF pattern. 
Figure 3.5: PCA result for the first two dimensions from VST transformed read 
counts of keratosis/hyperplasia and dysplasia samples based on LAF pattern. 
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Table 3.4: Candidate genes to differentiate LAF vs No LAF with OSCC excluded from PCA 
(positive logFC indicates greater expression in LAF group and vice versa) 
Gene ID HGNC symbol Average expression logFC Adjusted P value 
8733 GPAA1 4.02 -1.25 3.36E-02 
25790 CCDC19 0.68 -1.14 3.38E-02 
8751 ADAM15 7.64 -0.59 3.36E-02 
6093 ROCK1 4.67 0.56 3.36E-02 
5108 PCM1 5.98 0.53 3.03E-02 
 
Table 3.5: Candidate genes to differentiate LAF vs No LAF with OSCC and lichenoid samples 
excluded from PCA (positive logFC indicates greater expression in LAF group and vice versa) 
Gene ID HGNC symbol Average expression logFC Adjusted P value 
6093 ROCK1 4.49 0.61 4.88E-02 
5108 PCM1 5.88 0.58 4.88E-02 
9475 ROCK2 4.65 0.57 4.88E-02 
 
Supervised differential expression analysis 
Supervised analysis using sPLS-DA was utilized to try to identify genes which may differentiate 
samples based on LAF blanching patterns within each histological group. When all lesions were 
grouped together, due to the significant differences in gene expression between the different 
histological entities, they could not be separated based on LAF pattern (see Figure 3.6) Clear 
separation could be achieved between samples with and without LAF after excluding OSCC 
samples (see Figure 3.7). Fourteen differentially expressed genes were identified of which only two 
were considered relevant (see Table 3.6). When only keratosis and dysplasia samples were 
included, again those with and without LAF could be separated using sPLS-DA (see Figure 3.8) 
with 23 differentially expressed genes of which 4 were considered for further analysis (see Table 
3.7).  
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Figure 3.6: sPLS-DA result for first and second dimensions from VST 
transformed read counts of all samples by LAF pattern. 
 
Figure 3.7: sPLS-DA result for first and second dimensions from VST 
transformed read counts of all samples excluding OSCC by LAF pattern. 
59 
Table 3.6: Candidate genes identified from sPLS-DA to differentiate LAF vs No LAF after 
excluding OSCC samples 
Gene ID HGNC symbol LAF mean No LAF mean logFC LAF – No LAF 
8733 GPAA1 8.48 9.64 -1.16 
25790 CCDC19 5.47 6.47 -1.00 
 
Table 3.7: Candidate genes identified from sPLS-DA to differentiate LAF vs No LAF when only 
keratosis/hyperplasia and dysplasia samples are included 
Gene ID HGNC symbol LAF mean No LAF mean logFC LAF – No LAF 
8733 GPAA1 8.50 9.92 -1.42 
5013 OTX1 4.16 5.57 -1.42 
146433 IL34 7.78 9.12 -1.35 
9121 SLC16A5 7.65 8.42 -0.78 
 
 
Figure 3.8: sPLS-DA result for first and second dimensions from VST 
transformed read counts of keratosis/hyperplasia and dysplasia samples by LAF 
pattern. 
60 
In the above analysis, only a small number of candidate genes were identified and it was thought 
that differential gene expression between histological groups was masking the differences due to 
differential LAF. Therefore, to remove this confounding factor, each histological category was 
analysed separately to identify genes which separate the different LAF patterns. OSCCs were not 
analysed using this method due to the limited number of samples. In the keratosis group good 
separation was achieved with dimension one separating lesions without LAF from those with LAF 
while dimension two separated those with and without blanching (see Figure 3.9) Candidate genes 
were selected through direct comparisons between blanching groups (see Appendix C for a 
complete list). A total of 42 genes were identified separating those without LAF and LAF with no 
blanching, of which 9 were thought to be biologically relevant (see Table 3.8) while 45 genes 
differentiated those without LAF and LAF with blanching of which 9 were considered for further 
study (see Table 3.9). When comparing blanching in keratosis/hyperplasia lesions which lost 
fluorescence, 36 differentiating genes were identified of which 11 were considered for further study 
(see Table 3.10).  
 
 
 
 
 
 
 
 
Figure 3.9: sPLS-DA result for first and second dimensions from VST 
transformed read counts of keratosis/hyperplasia samples by LAF pattern. 
61 
Table 3.8: Candidate genes identified from sPLS-DA to differentiate keratosis/hyperplasia without 
LAF and LAF with no blanching 
Gene ID HGNC symbol No LAF mean LAF NB mean logFC No LAF – LAF NB 
10563 CXCL13 4.01 2.35 1.66 
3329 HSPD1 8.94 10.04 -1.09 
9774 BCLAF1 9.46 10.53 -1.08 
135228 CD109 10.33 11.40 -1.07 
8065 CUL5 8.79 9.72 -0.92 
1611 DAP 9.96 9.08 0.88 
10313 RTN3 8.74 9.61 -0.86 
8545 CGGBP1 8.60 9.44 -0.84 
79893 GGNBP2 8.39 9.18 -0.79 
NB = No blanching 
 
Table 3.9: Candidate genes identified from sPLS-DA to differentiate keratosis/hyperplasia without 
LAF and LAF with blanching 
Gene ID HGNC symbol No LAF mean LAF B mean logFC No LAF - LAF B 
1002 CDH4 2.35 4.05 -1.70 
10563 CXCL13 4.01 5.64 -1.63 
28559 TRBV28 2.59 4.04 -1.45 
445347 TRGC1 2.35 3.73 -1.39 
29851 ICOS 3.73 5.05 -1.33 
1493 CTLA4 4.43 5.62 -1.19 
2877 GPX2 10.32 9.20 1.12 
4345 CD200 5.39 6.45 -1.05 
135228 CD109 10.33 11.17 -0.84 
B = Blanching 
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Table 3.10: Candidate genes identified from sPLS-DA to differentiate blanching characteristics for 
keratosis/hyperplasia with LAF. 
Gene ID HGNC symbol LAF NB mean LAF B mean logFC LAF NB – LAF B 
10563 CXCL13 2.35 5.64 -3.29 
1493 CTLA4 3.86 5.62 -1.76 
2877 GPX2 10.95 9.20 1.75 
29851 ICOS 3.41 5.05 -1.64 
100506718 FLRT2 2.88 4.47 -1.59 
28559 TRBV28 2.50 4.04 -1.54 
4345 CD200 5.08 6.45 -1.36 
3486 IGFBP3 11.37 10.15 1.22 
55966 AJAP1 4.85 6.01 -1.16 
445347 TRGC1 2.81 3.73 -0.93 
28730 TRAJ25 2.35 3.24 -0.89 
NB = No blanching 
B = Blanching 
 
 
 
Again, the dysplasia group clustered together based on LAF patterns using the first and second 
dimensions with distinct clustering based on blanching characteristics (see Figure 3.10). Between 
dysplastic lesions without LAF and LAF with no blanching, 24 candidate genes were identified of 
which 8 were considered biologically relevant (see Table 3.11) while 24 genes were identified to 
differentiate no LAF and LAF with blanching of which 7 were considered relevant (see  
Table 3.12). Dysplastic lesions with LAF displayed less differences between those with and without 
blanching, with a total of 19 differentiating genes of which 11 were considered possible candidate 
genes (see Table 3.13) 
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Table 3.11: Candidate genes identified from sPLS-DA to differentiate dysplasia without LAF and 
LAF with no blanching 
Gene ID HGNC symbol No LAF mean LAF NB mean logFC No LAF – LAF NB 
3952 LEP 2.78 4.43 -1.65 
28646 TRAV36DV7 2.35 3.51 -1.16 
3623 INHA 2.51 3.66 -1.15 
3945 LDHB 8.88 10.01 -1.13 
200403 VWA3B 2.46 3.52 -1.06 
57678 GPAM 7.63 8.56 -0.93 
84925 DIRC2 9.14 8.22 0.92 
57799 RAB40C 9.24 8.41 0.84 
NB = No blanching 
 
Figure 3.10: sPLS-DA result for first and second dimensions from VST 
transformed read counts of dysplasia samples by LAF pattern. 
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Table 3.12: Candidate genes identified from sPLS-DA to differentiate dysplasia without LAF and 
LAF with blanching 
Gene ID HGNC symbol No LAF mean LAF Blanching mean logFC No LAF – LAF B 
7849 PAX8 7.26 5.69 1.57 
1281 COL3A1 13.92 15.24 -1.32 
6403 SELP 7.89 9.07 -1.18 
22918 CD93 9.88 10.98 -1.10 
7075 TIE1 8.64 9.71 -1.07 
5175 PECAM1 8.78 9.81 -1.02 
716 C1S 12.00 12.99 -0.99 
B = Blanching 
 
Table 3.13: Candidate genes identified from sPLS-DA to differentiate blanching characteristics for 
dysplasia with LAF 
Gene ID HGNC symbol LAF NB mean LAF B mean logFC LAF NB – LAF B 
2 A2M 12.23 13.49 -1.26 
3952 LEP 4.43 3.23 1.20 
200403 VWA3B 3.52 2.35 1.17 
7849 PAX8 6.80 5.69 1.10 
3299 HSF4 7.49 6.40 1.09 
7075 TIE1 8.63 9.71 -1.08 
6403 SELP 8.01 9.07 -1.06 
28646 TRAV36DV7 3.51 2.45 1.05 
440590 ZYG11A 4.68 3.73 0.96 
716 C1S 12.16 12.99 -0.83 
22918 CD93 10.17 10.98 -0.82 
NB = No blanching 
B = Blanching 
 
Within the lichenoid group, good separation was achieved between those with and without 
blanching using the first dimension, while a single case of oral lichen planus without any LAF was 
excluded in this analysis (see Figure 3.11). Only twelve genes were identified which separated these 
groups of which only one gene, PDF, was thought to be biologically relevant. A complete list of all 
candidate genes identified can be seen in Appendix C. 
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3.4 Discussion 
The current standard of care for an oral cancer screening examination is through visual and tactile 
inspection of the oral cavity, however it is well known that while this is highly efficacious in 
detecting lesions, visual inspection is a poor discriminator between benign and potentially 
malignant lesions.28 For this reason, a number of clinical adjuncts have been developed to assist 
practitioners in discriminating between high and low risk lesions, however, the current evidence 
does not support their routine use.6, 115 Nonetheless, recent evidence has found that VELscopeTM is 
efficacious in identifying high risk lesions in routine screening.131, 133, 156 Previous studies have 
discussed the significance of blanching, or diascopic fluorescence, and hypothesised about the 
biological significance of this, however, to date no studies have been able to elucidate the reason for 
this occurrence.127, 156 The present study is the first to our knowledge to explore the underlying 
causes of autofluorescence in the oral mucosa with an emphasis on blanching at the molecular level.  
Figure 3.11: sPLS-DA result for first and second dimensions from VST 
transformed read counts of lichenoid samples by LAF pattern. 
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In our initial analysis, of particular interest lichenoid lesions and OSCCs tended to cluster together 
while dysplasia and keratosis/hyperplastic lesions tended to cluster together (see Figure 3.3). One 
would expect that dysplasia would be more similar to OSCC on a molecular level than lichenoid 
lesions. While further analysis is required, this may be due to similarities in the inflammatory 
profile of both conditions, with both OSCCs and lichenoid lesions displaying a strong inflammatory 
reaction. Furthermore, apoptosis may be a contributing factor although OSCC would more likely be 
associated with anti-apoptotic proteins and lichenoid lesions with pro-apoptotic proteins. Further 
research is required in this area, particularly with the controversy regarding the malignant potential 
of oral lichen planus.  
When assessing for differences based on LAF when all histological diagnoses were combined, it 
was difficult to separate the groups. CEBPA, a known tumour suppressor gene involved in SCCs of 
the head and neck and PCM1 which has been shown to be involved in cell division and mutations 
associated with ovarian cancer,163, 164 were differentially expressed (see Table 3.3). When OSCCs 
were excluded, a number of genes thought to be involved in tumour progression were identified (see 
Table 3.4) such as GPAA1 which is known to be up regulated in head and neck squamous cell 
carcinoma, CDC19 a tumour suppressor gene which has been shown to be down regulated in 
nasopharyngeal carcinoma and both ADAM15 and ROCK1 which have been associated with other 
cancer types.165-169 Removing both OSCCs and lichenoid samples revealed differential expression 
of ROCK1 and ROCK2, both of which are involved in cell invasion and migration in SCC of the 
tongue and have been identified as potential targets for inhibition in cancer therapy (see Table 
3.5).170, 171 Supervised analysis uncovered further genes with known roles in cell cycle regulation 
and other cancer types (see Table 3.6 and Table 3.7).172-174  
The genes identified with histological groups combined appear more relevant to understanding the 
progression from benign keratosis towards malignancy, but do not seem to elucidate differences in 
fluorescence pattern. The reason for this is that there are multiple contributing factors for LAF 
including angiogenesis, inflammation, stromal remodelling as well as light scattering due to 
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enlargement of cell nuclei. Each of our histological diagnoses could have differing reasons for 
respective LAF, with keratosis and lichenoid lesions losing fluorescence due to inflammation while 
dysplasia and OSCC could lose fluorescence due to all the aforementioned reasons. Any unifying or 
differentiating factors within each fluorescence category were not found, possibly due to the 
overarching differences in gene expression between histological categories providing a much 
stronger signal than the subtle differences which contribute to fluorescence. Therefore, further 
analyses were performed on each histological group independently.  
Within the dysplasia group, it was hypothesised that LAF would be related to inflammation, 
angiogenesis, alterations in the stroma, enlargement of cell nuclei as well as metabolic changes. It 
appears that within the blanching and no blanching groups, there were some similarities but also 
differences with regards to the possible reasons for LAF when compared to each other and also 
when compared to those without LAF. Both LAF groups displayed increased expression of genes 
involved in angiogenesis but through different pathways. In the no blanching group, LEP and 
VWA3B were overexpressed compared to dysplasia without LAF and LAF without blanching (see 
Table 3.11 and Table 3.13). LEP is known to have a role in angiogenesis in the oral mucosa during 
wound repair, and in colorectal carcinoma has been shown to promote adhesion and invasion.175, 176 
While its role in oral cancer is yet to be explored, it could play a similar role to that in colorectal 
carcinoma considering LEP has known angiogenic potential in the oral mucosa.175, 177 Of great 
interest, VWA3B is a common marker used for angiogenesis and displays increased expression in 
oral epithelial dysplasia, but is also known to bind to collagen types I, II, III and IV and may play a 
dual role with regards to LAF by promoting angiogenesis and also disrupting the collagen 
matrix.178-181 Compared to those without LAF, dysplasias with LAF and no blanching expressed 
increased levels of INHA and LDHB. Both of these genes have been implicated to play a role in 
tumour progression in other cancer types, and although their role in OSCC has not yet been 
explored, this may be indicative of a higher grade of dysplasia.182, 183 The no blanching group also 
displayed increased expression of HSF4, a gene involved in cellular senescence possibly indicating 
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differing grades of dysplasia.184, 185 It is known that increased angiogenesis is seen with increasing 
grades of dysplasia, and this may indicate a higher likelihood of visualising LAF with more severe 
grades of dysplasia.186 This is in agreement with previous evidence that autofluorescence has a 
higher sensitivity for high grade dysplasia compared to low grade dysplasia.187 None of the 
candidate genes displayed any association with changes in cell nuclei, however, it is believed 
increased severity of dysplasia would present with greater changes in cellular morphology. With the 
results of the present study, the relation of this to LAF is uncertain. 
Those in the LAF with blanching group appear to follow a different pathway with regards to 
angiogenesis with increased expression of PECAM1, a well-defined vascular marker implicated in 
angiogenesis related to development of OSCCs (although increased expression of PECAM1 may 
also be due to its role in inflammation), and TIE1, which has yet to be studied in the context of the 
oral mucosa, but has been implicated in angiogenesis and the ANGPT-TIE pathway is considered a 
target for upcoming anti-angiogenic drugs .135, 188-191 In support of the inflammatory hypothesis, 
dysplasia with LAF and blanching were associated with increased expression of CD93 and C1S (see  
Table 3.12 and Table 3.13) compared to those both without LAF and LAF without blanching, both 
of which are involved in inflammation; C1S  through the complement pathway, and CD93 through 
multiple pathways which are still under investigation.192, 193 Additionally, increased expression of 
COL3A1in the dysplasia group with blanching indicates increased production of type III collagen, 
which may cause stromal alterations as normally type I collagen is predominantly found in the oral 
mucosa, although COL3A1 may also influence the development of type I collagen.194 Some other 
candidate genes identified have implications in other cancers or cancer related processes although 
their exact role in this scenario is unclear. These include including PAX8 (implicated in 
adenocarcinoma and ovarian carcinoma), SELP (nasopharyngeal carcinoma) and RAB40C (gastric 
cancer).195-198 
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As previously discussed, we hypothesised that the biological causes for LAF varied between the 
histological groups making it difficult to differentiate all samples based on LAF alone. In support of 
this, the differential expression profile between the LAF groups within the keratosis/hyperplasia 
group present different underlying mechanisms to those in the dysplasia group. CXCL13 is a 
chemoattractant for B-cells and is involved in the inflammatory response, and was associated with 
over-expression in the group with blanching, while being under expressed in the group without 
blanching when compared to keratosis without LAF. 
Within the keratosis group presenting with LAF with blanching, there was over expression of 
TRBV28 and TRGC1 compared to both no LAF and LAF without blanching groups, and also over-
expression of TRAJ25 compared to keratosis with LAF and no blanching. All three are components 
of the T-cell receptor indicating up-regulation of T-cell mediated inflammation in those which 
present with blanching (see Table 3.9 and Table 3.10). However, CTLA4, ICOS and CD200 which 
are all related to suppression of T-cell mediated immunity were also over-expressed in the 
blanching group compared to both of the other experimental groups. CTLA4 encodes for a cytotoxic 
T-cell associated protein and in mucosal immunity, plays a role in suppressing T-cell inflammation, 
particularly in the context of induction of oral tolerance.199, 200 CD200 has been known to be 
exploited by pathogens in suppressing the immune response, as well as in certain cancers to reduce 
the host inflammatory response against tumours.201, 202 While CD200:CD200R1 interaction leads to 
down-regulation of T-cells, CD200 itself is found on multiple cell types, including activated T-cells 
and can be used as a marker to signal the presence of activated T-cells.201 CTLA4 has a similar 
property, as it is only expressed at very low levels in naïve T-cells but is greatly amplified on 
activation.203 ICOS is involved in regulation of all T helper subsets and is over-expressed at an early 
stage following T-cell activation, after which it is involved in T-cell regulation, proliferation and 
survival.204, 205 Additionally, lesions displaying LAF without blanching displayed under-expression 
of GPX2 which is associated with an anti-inflammatory role and is known to prevent inflammation 
against microflora in the gastrointestinal tract.206-209 Overall, it appears that LAF with blanching in 
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the keratosis/hyperplasia group is associated with an increased inflammatory response, largely a T-
cell mediated response. Keratosis and epithelial hyperplasia in the oral environment occurs due to 
protective and proliferative changes in the oral mucosa due to chronic irritation. With this in mind, 
inflammatory changes are to be expected in response to chronic irritation of the oral mucosa. 
Within the keratosis group presenting with LAF and no blanching, the candidate genes separating 
these from those without LAF were those related to cell cycle, rather than inflammation (see Table 
3.8 and Table 3.10 ). All of the candidate genes identified separating these two groups, with the 
exception of CXCL13 are involved in regulation of cellular growth and proliferation. RTN3, CUL5 
and BCLAF1 are all involved in apoptosis, although out of the three only CUL5 has a well-defined 
pathway; and all of these were over-expressed in the LAF with no blanching group when compared 
to no LAF.210-212  DAP is also involved in apoptosis, but displayed decreased expression in this 
group.213 Both CGGBP1 and GGNBP2 are known to regulate various checkpoints in the cell 
cycle.214, 215 Of particular interest, HSPD1, which encodes Heat shock protein 60 was found to be 
over expressed in the no blanching cohort. Heat shock proteins are intracellular molecules and their 
release into the extracellular environment is an indication of non-physiological damage.216 Heat 
shock protein 60 (Hsp60) is associated with increased expression of E-selectin, ICAM-1 and 
VCAM-1 on vascular endothelial cells.216 The increased expression of Hsp60 could be indicative of 
cellular damage, possibly through trauma. This would be consistent with the over-arching theme of 
over-expression of genes involved in apoptosis, proliferation and cell cycle regulation, as all of 
these pathways are over-expressed during wound healing of the oral mucosa.217, 218 CD109, another 
gene over-expressed in the LAF with no blanching group is associated with regulation of TGF-β 
which plays a vital role in wound closure.219 We have previously shown that in a clinical scenario, 
areas with LAF and no blanching displayed the highest rate of healing following a review period 
which would be consistent with the present findings if this were associated with acute trauma.156 
Within lichenoid lesions, it is hypothesised that LAF is a result of intense inflammation, and the 
evidence with regards to the dysplasia group indicates that inflammation does play a role in LAF. 
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Unfortunately, the causes for blanching within the lichenoid cohort could not be elucidated from the 
data provided. Only PDF; an oncogene involved in cell proliferation in colon, lung and breast 
cancers, was identified as a potential candidate gene.220 Another potential gene of interest is 
SERPINE3, as the Serpin family is known to have roles in inflammation, immune function, 
tumorigenesis among others, however the role of SERPINE3 is yet to be elucidated.221  
The aim of this study was to elucidate potential candidate genes or pathways to explain the reasons 
for LAF and also provide molecular evidence for the phenomenon of diascopic fluorescence. As 
expected no unifying factor could be found which may explain LAF in the different histological 
groups assessed, as there are multiple biological processes which are thought to lead to LAF, and 
differing clinical lesion types will express this phenotype due to different underlying mechanisms. 
Nonetheless, we were able to find candidate genes and pathways which may explain LAF within 
each histological category.  
Overall, LAF appeared to occur due to angiogenesis, inflammation, as well as breakdown of the 
stromal architecture. In angiogenesis, increased vessel density introduces additional blood flow to 
the area which in turn increases light absorption resulting in LAF. Dysplastic lesions with LAF 
were associated with increased angiogenic activity. Increased blood flow is also a hallmark of the 
inflammatory process which accounts for the increased signs of inflammation in both dysplasia and 
keratosis with LAF, particularly in the cohort with blanching. Furthermore, inflammation may also 
be a host response to dysplastic cells and can be found in 80% of cases of epithelial dysplasia.222, 223 
Breakdown of the collagen matrix by matrix metalloproteinases to facilitate invasion is an 
established feature of oral malignancies and this can further contribute to LAF.224 Gene expression 
analysis in the dysplasia with LAF group found deregulation in collagen production which may be 
associated with breakdown of stromal architecture. It was also hypothesised that morphological 
changes in cell nuclei may also contribute to LAF by increasing scattering of excitation light. In the 
present study, there were no specific genes which indicated nuclear changes however the data does 
seem to indicate that more severe grades of dysplasia are associated with LAF, and increased 
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severity of dysplasia would presumably be associated with additional changes in the nuclear 
architecture. NADH and FAD have also been implicated in fluorescent spectroscopy of the oral 
mucosa and it has been proposed that decreased FAD due to increased metabolism may lead to LAF 
in dysplasia. In the present study, cellular metabolism was not seen to be a major factor based on 
the differentially expressed gene profile. Previous studies have found that epithelial dysplasia 
actually displays an increase in epithelial fluorescence, with LAF being associated with stromal 
changes. Therefore while NADH and FAD may be known fluorophores and actually display 
increased fluorescence with dysplasia, with regards to VELscope™ they appear to have limited 
applicability. 
Due to the limited number of samples, molecular characteristics of OSCCs and their relationship to 
LAF could not be elucidated from the current study. However, it is possible to extrapolate from the 
information gained from the other histological groups. OSCC is known to have increased 
angiogenesis, cell cycle deregulation, elicits an inflammatory response from the host and is 
associated with stromal breakdown to facilitate invasion. Therefore, LAF in OSCCs would most 
likely be due to a combination of all of the above features. Further, OSCCs may have areas of 
dysplasia surrounding the tumour focus, and the diascopic effect may be due to these areas 
blanching themselves rather than the tumour core. Further studies with detailed clinical data and 
paired biopsies would be required to assess this hypothesis, but this does not detract from the 
findings of the other histological groups or the applicability of the phenomena of LAF and diascopy 
in assessment of oral mucosal lesions. 
One of the limitations of this study is the small sample size. Given that the main aim was to find 
candidate genes and pathways which may be associated with LAF, further work is required to 
validate these pathways using Real-time quantitative PCR (RT-qPCR) on a larger sample size to 
confirm the findings of the present study. A drawback with the current approach is that the sample 
size is small compared to the size of the data being collected, which means that this may be liable to 
change if a different set of samples were to be used.225 Therefore, it cannot be concluded that the 
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genes identified in the current study alone are responsible for LAF, but rather should be interpreted 
as representing pathways which when deregulated during the disease process, may be responsible 
for differing fluorescence patterns. Different disease processes may share deregulated pathways. 
For example, in the current study, inflammation is commonly associated with all four disease 
processes represented in the cohort, and our data indicates that genes related to inflammation are 
over-expressed in the groups displaying LAF with blanching. Additionally, a number of 
differentially expressed genes in this cohort are either uncharacterized or their function is unknown 
at present therefore their importance in the context of LAF is yet to be elucidated. Furthermore, 
genes which have been studied may have multiple functions which are yet to be revealed. For 
example, DYX1C1 was the most highly differentially expressed gene in the keratosis group and 
seemed to represent a progression from no LAF to LAF with blanching to LAF without blanching. 
Currently, this gene appears to be related to dyslexia which superficially may appear unimportant in 
this context, however a recent study has found expression of DYX1C1 to be a predictor of poor 
prognosis in breast cancer, and its implications for oral disease require further work in the context 
of this study.226, 227 
3.5 Conclusion 
Multiple pathways may result in LAF of oral mucosal lesions when visualised under VELscopeTM. 
LAF may occur due to inflammation, angiogenesis, changes in cell cycle, or breakdown of stromal 
architecture. In dysplasia, LAF appears to be due to a combination of inflammation, angiogenesis, 
changes to the stromal structure and also cell cycle deregulation. In keratosis, LAF appears to be 
due to both inflammation and cell cycle deregulation. In both keratosis and dysplasia, the 
phenomenon of blanching appears to be closely related to inflammation. 
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Chapter 4: General Discussion 
4.1 Introduction 
This thesis sought to explore the efficacy of VELscopeTM in general dental practice for routine 
screening of oral mucosal lesions, and also assess a standard decision making protocol dentists can 
follow when utilising this technology. In addition, we sought to explore biological mechanisms for 
loss of autofluorescence with the aim of incorporating this into clinical practice to better make 
clinical decisions regarding VELscopeTM findings. The proposed decision making protocol was 
shown to be highly efficacious in helping identify OPMDs and allowed a greater sensitivity when 
compared to a conventional oral examination in a general practice environment, without a large 
drop in specificity.156 In addition, relationships between LAF and clinical characteristics were 
identified. Further, biological pathways related to LAF and their correlation with underlying 
biological mechanisms were uncovered. 
4.2 Changing the head and neck examination 
In Australia, approximately 62% of the adult population attend the dentist over a 12 month 
period.228 With the dental practitioner’s intimate knowledge of head and neck anatomy, this places 
them in an ideal situation to provide opportunistic screening for head and neck cancer. Considering 
that more than 90% of these are OSCCs, the oral mucosal examination is an important component 
of any patient examination.153 The head and neck examination should include visual inspection of 
the entire oral cavity and the oropharynx, as well as the lips and surrounding tissues under a white 
light source. Bimanual palpation of the neck is also an important part of the examination process to 
help assess for localised metastases of head and neck tumours, particularly to identify tumours 
which cannot be visualised in the oral cavity. However, even with this approach, unfortunately the 
diagnosis of oral cancer is often delayed resulting in poor treatment outcomes for patients.9, 12 This 
is despite the oral cavity being an area which is easily visualised by the medical or dental 
practitioner. 
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While a number of technologies have become available to improve the examination process, none 
of them have enough evidence supporting their efficacy to promote widespread use. VELscopeTM 
has been shown to be efficacious in identifying dysplasia, however a number of false positives have 
been reported hindering its use in general practice.103, 124, 125, 127, 128, 132, 148 These are largely to do 
with the confounding factor of benign inflammatory conditions which may also display LAF. While 
the use of a review appointment has previously been discussed to reduce the rate of false positives 
associated with the device,131, 133 this is the first study to evaluate a decision making protocol which 
assesses the impact of a review and its relation to clinical features. It is envisaged that incorporation 
of this decision making protocol into the head and neck examination will simplify screening of 
patients while improving efficacy of the conventional oral examination. 
4.3 Biological determinants of autofluorescence 
Before using adjunctive aids such as VELscope™ in the clinical environment, it is important to 
understand the biological processes underpinning its use so that the clinician understands the 
relevance of the findings, but also the limitations of the technology. What this study has shown is 
that there are a number of biological mechanisms which contribute to LAF in both benign and 
neoplastic lesions. While there is a cross-over of pathways which may contribute to this 
phenomenon, there are differing properties of each histological type which contribute to the 
presenting phenotype with regards to fluorescence pattern. 
With regards to benign conditions such as keratosis or hyperplasia, LAF with blanching appears to 
be related to inflammatory processes; in particular T-cell mediated inflammation. Benign keratosis 
and hyperplasia is a protective response of the oral mucosa to chronic irritation and there is a 
resultant accumulation of chronic inflammation. With this in mind, it is no surprise that genes 
related to the adaptive immune system are over-expressed in this cohort. With regards to the group 
with LAF and no blanching in the keratosis group, a number of genes related to apoptosis and cell-
cycle regulation, which would normally be associated with tumorigenesis, were found to be over-
expressed. However, the same pathways have been shown to be involved in wound healing.217, 218 In 
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a clinical context, keratosis or hyperplasia are the result of chronic irritation, particularly the lesions 
in the cohort presented in Chapter 3 which are persistent lesions referred to a specialist. However, 
such lesions, being in areas of persistent trauma, are also prone to acute injuries which may prompt 
the wound repair response. It is not uncommon to see patients with keratosis on the buccal mucosa 
due to chronic irritation, but also have acute episodes of pain due to a particularly severe traumatic 
event which would elicit a wound repair response. This correlates well with the clinical chapter 
where lesions with unexplained LAF and no blanching displayed the highest rate of healing among 
reviewed lesions, as acute traumatic events would be expected to heal over a two week period. This 
also raises the importance of a review period of any areas with LAF which cannot be explained on 
clinical grounds to help eliminate false positives. Due to the constant forces of mastication and 
parafunction, acute traumatic events are a common occurrence in the oral environment and in 
general dental practice should be considered a differential diagnosis for any unexplained areas with 
LAF at the initial examination. 
In dysplastic lesions, LAF appeared to be related to gene expression associated largely with 
angiogenesis, inflammation and changes in the stromal architecture. Inflammation is commonly 
seen in oral epithelial dysplasia, with 80% of lesions displaying a protective inflammatory 
response.222, 223 However, when inflammation is present with epithelial dysplasia, this can prove to 
be a confounding factor when diascopic fluorescence is concerned. Often, dysplasia will present 
itself in a background of OLP and clinically, it can be difficult to detect or exclude the presence of 
dysplasia or choose the site to biopsy. In these cases, LAF may prove to be a challenging feature to 
use in differentiating between benign and neoplastic processes. In the present study, dysplastic 
lesions with LAF over-expressed genes related to angiogenesis compared to those which did not 
present with LAF. Previous studies have shown that angiogenesis is a marker of the progression 
from benign mucosa to malignancy, with greater rates of angiogenesis being seen with higher 
grades of dysplasia.229 Therefore, it would be expected that more severe cases of dysplasia are more 
likely to display LAF. Previous clinical studies have shown that VELscope™ has a higher 
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sensitivity for high grade dysplasia when compared to low grade dysplasia.187 It may be 
extrapolated that VELscope™ may prove to be a more useful tool in monitoring lesions which have 
previously proven to be dysplastic, with changing LAF patterns being indicative of progression of 
the disease process although a clinical trial would be required to assess the clinical applicability of 
this hypothesis.  
While the data did not provide answers with regards to LAF in the context of OSCCs, it is possible 
to extrapolate based on the information available. It is known that OSCC is a progression from 
dysplasia resulting from further driver mutations in the dysplastic cells, eventually resulting in 
cellular invasion past the basement membrane. Angiogenesis and breakdown of the stromal 
architecture are pertinent to invasion of the mutated cells. Additionally, the tumour elicits an 
inflammatory response from the host. Considering all of the above biological causes for LAF are 
increased in OSCCs, it is of no surprise that in the literature, there are currently no reported cases of 
OSCCs which have not lost fluorescence. With this knowledge, VELscopeTM can provide a vital 
tool for the delineation of surgical margins in the removal of OSCCs. Considering that dysplasia 
can be found even 20mm from the clinically visible margin of OSCCs, and that invasive carcinoma 
has been found 10mm from the tumour margin, it is important to uncover new methods of 
determining appropriate excisional margins.230 Currently, OSCCs are excised with a degree of 
clearance around the visible tumour; however VELscopeTM provides an opportunity to provide a 
more accurate margin of excision which may reduce the occurrence of secondary tumours. Previous 
research has found cleaner margins based on direct tissue fluorescence compared to normal clinical 
margins.123 
4.4 Autofluorescence and clinical context 
One of the shortcomings in the previous literature is that LAF has been considered with a lack of 
context and no clinical correlation. VELscopeTM was developed as a clinical adjunctive tool and not 
a diagnostic device, and when LAF is considered without any clinical correlation, the resulting 
accuracy is poor. For example, McNamara et al proceeded to biopsy every lesion with persistent 
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LAF without considering the clinical context, and resulted in unnecessary biopsies of lesions such 
as chronic mucositis, benign melanosis or even a case of lymphoid tissue on the lateral tongue.132 A 
simple clinical review would find that a case such as the latter would be consistent with the lingual 
tonsils, while benign melanosis is a common finding which in most cases, can be confidently 
diagnosed clinically without the need for a biopsy.  
When looking at the significance of blanching, it has previously been suggested that lesions with 
LAF with no evidence of blanching have been associated with dysplasia; the results from the 
present study indicate that those which blanch partially were more likely to require follow-up.127, 156 
This could perhaps be explained by the fact that pigmented lesions, and often traumatic lesions with 
extravasated blood account for a large portion of lesions which present with LAF and do not blanch, 
and these can be discounted as benign based on clinical appearance. Pigmented lesions display LAF 
due to absorption of light from melanin while in traumatic lesions with extravasated blood; the 
haemoglobin is responsible for absorption of light. Neither melanin nor extravasated haemoglobin 
will be displaced on pressure therefore these lesions will not display diascopic fluorescence. 
Therefore, re-examination of areas with LAF are an important part of the proposed decision making 
protocol as these lesions can on clinical grounds account for LAF. Dysplastic lesions lose 
fluorescence due to a combination of architectural changes to the oral mucosa as well as 
angiogenesis and inflammation. Angiogenesis and inflammation lead to increased vascularity in the 
area bringing in haemoglobin which results in LAF. However, on pressure, intravascular 
haemoglobin may be displaced resulting in a return to a normal fluorescence pattern in areas where 
this is the sole reason for LAF. Areas which lose fluorescence due to architectural changes in the 
oral mucosa and the underlying connective tissue will not display diascopic fluorescence, as 
pressure will not elicit any changes in the underlying connective tissues. In dysplasia, LAF is due to 
both architectural changes as well as changes in vascularity, leading to areas which blanch and areas 
which do not, presenting as what is otherwise referred to as partial blanching. This may explain why 
lesions with LAF and partial blanching were considered the most suspicious in the clinical arm of 
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the present studies. Lesions which display LAF due to inflammation alone such as chronic irritation 
from dentures present this way primarily due to changes in vascularity. Hence, these lesions are 
more likely to present with LAF and complete blanching as the haemoglobin within the vasculature 
is displaced on pressure. It is for this reason, that only lesions which display complete blanching are 
considered negative for LAF in the decision making protocol. Considering that stromal changes are 
required for invasion of epithelial cells, dysplastic lesions which display LAF but do not blanch 
may be considered to be more advanced than those which present with blanching, as this may 
indicate a greater stromal component to LAF.  
With regards to the previously discussed difficulties in identifying dysplasia in a background of 
OLP, VELscopeTM could be used to assist surveillance of patients with established lesions and also 
contribute to the choice of site of biopsy. Previous research has found that even with meticulous 
follow-up, malignant changes in OLP can be overlooked based on a clinical examination alone, and 
one of the most challenging aspects for a clinician is to choose the site of biopsy particularly when 
widespread changes are apparent.27 With fluorescence visualization, areas which display LAF and 
do not blanch could be indicative of changes in the stromal architecture, which are associated with 
malignant transformation but not a feature associated with OLP. Only one gene, PDF, was found to 
differentiate lichenoid lesions with and without blanching, although this gene has been associated 
with other cancer types. Further research with a larger sample size comparing properties of biopsies 
of OLP from sites with and without blanching when viewed with autofluorescence is required. 
Unfortunately VELscopeTM cannot differentiate between angiogenesis and inflammation however 
further research should also focus on developing other technologies which can be incorporated into 
the device to further subdivide lesions with LAF based on their underlying biological cause, rather 
than relying on diascopic fluorescence alone. IdentafiTM is another device which uses 
autofluorescence in combination with reflectance spectroscopy, with the second feature aiming to 
highlight vasculature associated with angiogenesis. However inflammatory conditions have also 
been associated with increased vascularity when viewed with IdentafiTM limiting its applicability.231 
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Narrow band imaging (NBI) is another technology designed to highlight vasculature underneath 
mucosa.115, 232 In screening of patients with Barrett’s oesophagus, the use of NBI following 
autofluorescence with endoscopic techniques reduced the false positive rate associated with 
autofluorescence on its own from 40% to 10% without compromising sensitivity. In assessment of 
patients with head and neck cancer using a combination of autofluorescence and NBI by endoscopy, 
an increased specificity was associated with NBI as only changes in vasculature were visualised, 
and this was not influenced by inflammation of the mucosa.233 The sensitivities for both 
autofluorescence and NBI individually in this scenario were 96%, therefore overall NBI was a more 
accurate technology in detecting head and neck cancer. The combined use of both autofluorescence 
and NBI impacted on the definitive management of 15.1% of patients through the detection of 
additional lesions.233 A similar technique may be utilised in the oral cavity, through the combination 
of technologies to help differentiate dysplastic lesions with LAF from benign inflammatory 
conditions with LAF when they cannot be distinguished on clinical grounds alone. 
It is only through understanding biological reasons why LAF occurs and the clinical context, that 
appropriate decisions can be made when utilising VELscopeTM in clinical practice. By combining 
the proposed decision making protocol along with the knowledge underpinning the biological 
reasons for autofluorescence, it is envisaged that VELscopeTM could gain widespread use in both 
general and specialist practice for screening, visualising and monitoring of oral mucosal lesions. 
Further research is required on the applicability of using VELscopeTM in monitoring of patients with 
existing OPMDs. The combination of different technologies should also be explored to help 
improve the overall accuracy of autofluorescence. 
4.5 Limitations and future approaches 
As addressed in chapter 2, one of the limitations of the available data is that it is a single centre, 
single operator trial and the results may differ with operators with differing background knowledge 
of oral mucosal pathology. Future directions with this research would be to test the efficacy of this 
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decision making protocol among multiple health practitioners in multiple centres with various levels 
of training in oral mucosal pathology to assess the generalizability of the current findings.  
Another limitation with the data available is that it looks at the state of patients at the current stage, 
with no future follow up. In the clinical study, there were five diagnosed cases of dysplasia, all on 
the lip, among three hundred and five patients giving a prevalence of 1/61 or 1.6% in the study 
population. However, the incidence rate of OSCCs of the lip, the most common site of OSCCs in 
Australia is only 5.3 per 100,000 population per year, suggesting that there is a large likelihood that 
none of these lesions would have progressed to malignancy. However, with current knowledge, it is 
impossible to predict progression of dysplasia to malignancy.234 While one would assume severe 
dysplasia to be associated with a higher rate of progression compared to mild dysplasia, studies 
have found no significant association between grade of dysplasia and rates of progression.234 
Molecular studies assessing genetic mutations and differential gene expression association with 
malignant progression may provide methods of predicting the risk of progression of dysplastic 
lesions in the future, however currently this research is ongoing. Therefore, with current knowledge 
all OED should be treated as one and the same, and the role of the general practitioner should be to 
detect all oral mucosal lesions with possible dysplasia which can then be managed appropriately by 
specialist practitioners.234  
Further studies could look at following up patients screened with VELscopeTM or cross-matching 
patients with those on the Queensland Oncology Repository (QOR) to see if any cases of OED 
detected in the study did progress to malignancy, or to determine if any patients who did not present 
with sinister pathology at the initial examination subsequently developed OSCC. This could 
particularly be applicable to further large scale trials of this decision making protocol, to assess if 
the incorporation of VELscopeTM into the oral examination, and subsequent treatment of detected 
OPMDs, leads to a reduction in the prevalence of OSCCs at a five or ten year follow-up period 
compared to a matched control population.  
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With regards to the sequencing data, the main limitation is that associated with NGS. Due to the 
complexity and expense of the technology, it was only possible to assess a limited number of 
samples. In addition, the data generated from RNA-Seq can be difficult to replicate in a different 
cohort which may differ from the present study, particularly as a multitude of genes may be 
involved with LAF and as such a single cohort study is unlikely to capture all of those involved.225 
However, the aim of the present study was to find candidate genes and pathways which may 
differentiate lesions with and without LAF and this aim has been achieved. Future directions would 
be confirmatory in nature to assess differential gene expression using Real-Time quantitative PCR 
(RT-qPCR) and also relative protein expression using immunohistochemistry specifically targeting 
genes and proteins involved in pathways related to angiogenesis, inflammation and cell cycle 
regulation.  
4.6 Conclusion 
Direct fluorescence visualisation in the context of oral cancer screening has been available to dental 
practitioners since 2007 with the release of VELscopeTM, however, its uptake has been limited. The 
main reason for this has been the ambiguity with regards to a clinical protocol when using the 
device to differentiate benign and potentially malignant lesions as both may display LAF. LAF of 
the oral mucosa is associated with angiogenesis, inflammation and cell cycle regulation. In benign 
lesions, LAF can be associated with chronic inflammation or acute trauma. In dysplasia, LAF is 
associated with angiogenesis, inflammation and cell cycle regulation. Diascopic fluorescence is a 
result of chronic inflammation in both keratosis and dysplasia. By following a protocol which 
includes clinical features of the lesion and reviewing lesions when unsure taking into account 
biological considerations for LAF, a reduction in the number of unnecessary referrals when 
compared to using LAF alone can be achieved. The addition of direct tissue fluorescence to routine 
screening of the oral mucosa can be used to improve the detection of OPMDs in general dental 
practice, and detect areas of dysplasia which may not be detected on COE. Further research is 
required on the use of autofluorescence to monitor patients with existing OPMDs and also on the 
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combined use of different technologies to raise the overall accuracy of adjunctive aids in the 
detection of epithelial dysplasia. 
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Table A.1: Sample characteristics and mapping statistics 
Sample ID Histological diagnosis LAF pattern Input Reads Mapped Reads Mapping Rate 
OMP.2E10.01 Dysplasia LAF with blanching 51,396,334 47,250,055 0.919 
OMP.3C10.01 Dysplasia LAF with blanching 57,354,386 51,664,444 0.901 
OMP.5B07.01 Dysplasia LAF with blanching 59,231,482 55,190,937 0.932 
OMP.5F04.01 Dysplasia LAF with blanching 63,913,435 59,603,305 0.933 
OMP.5G09.01 Dysplasia LAF with blanching 51,699,405 46,871,620 0.907 
OMP.2B05.01 Dysplasia LAF no blanching 43,433,692 37,647,700 0.867 
OMP.4B08.01 Dysplasia LAF no blanching 52,861,994 45,950,052 0.869 
OMP.4B09.01 Dysplasia LAF no blanching 55,052,325 45,887,687 0.834 
OMP.4B12.01 Dysplasia LAF no blanching 40,999,563 34,764,930 0.848 
OMP.4F05.01 Dysplasia LAF no blanching 54,806,361 50,501,965 0.921 
OMP.2C10.01 Dysplasia No LAF 47,789,767 42,696,188 0.893 
OMP.5B06.01 Dysplasia No LAF 64,263,668 58,877,467 0.916 
OMP.5C07.01 Dysplasia No LAF 53,197,548 48,878,501 0.919 
OMP.5G03.01 Dysplasia No LAF 63,405,522 58,827,688 0.928 
OMP.5G04.01 Dysplasia No LAF 42,315,850 22,083,770 0.522 
OMP.1H05.01 Keratosis LAF with blanching 67,830,441 62,664,113 0.924 
OMP.2C06.01 Keratosis LAF with blanching 44,774,646 26,232,343 0.586 
OMP.2D10.01 Keratosis LAF with blanching 42,763,853 39,019,945 0.912 
OMP.2E05.01 Keratosis LAF with blanching 56,576,189 52,064,448 0.92 
OMP.5F09.01 Keratosis LAF with blanching 60,464,911 56,613,480 0.936 
OMP.1G03.01 Keratosis LAF no blanching 72,954,305 64,933,338 0.89 
OMP.2A05.01 Keratosis LAF no blanching 44,519,716 39,181,258 0.88 
OMP.2B02.01 Keratosis LAF no blanching 40,253,940 35,093,974 0.872 
OMP.2G10.01 Keratosis LAF no blanching 40,773,362 32,450,442 0.796 
OMP.3D04.01 Keratosis LAF no blanching 53,487,669 48,661,708 0.91 
OMP.5B01.01 Keratosis LAF no blanching 53,401,709 46,850,761 0.877 
OMP.1F07.02 Keratosis No LAF 45,151,381 42,139,035 0.933 
OMP.1F12.01 Keratosis No LAF 52,289,714 47,133,547 0.901 
OMP.3G09.01 Keratosis No LAF 48,903,257 45,334,218 0.927 
OMP.5F12.01 Keratosis No LAF 42,867,134 26,402,681 0.616 
OMP.1G01.01 Lichenoid LAF with blanching 69,395,197 62,590,245 0.902 
OMP.1H08.01 Lichenoid LAF with blanching 42,665,929 38,177,216 0.895 
OMP.3G11.01 Lichenoid LAF with blanching 57,449,882 51,063,290 0.889 
OMP.5E07.01 Lichenoid LAF with blanching 54,459,758 51,268,126 0.941 
OMP.5F11.01 Lichenoid LAF with blanching 53,922,269 50,593,915 0.938 
OMP.1G07.01 Lichenoid LAF no blanching 56,726,968 53,644,921 0.946 
OMP.2B09.01 Lichenoid LAF no blanching 48,871,110 42,870,036 0.877 
OMP.2C05.01 Lichenoid LAF no blanching 57,666,252 52,358,257 0.908 
OMP.3B01.01 Lichenoid LAF no blanching 44,326,396 39,838,000 0.899 
OMP.1F03.01 Lichenoid No LAF 51,016,373 44,900,275 0.88 
OMP.3G02.01 OSCC LAF with blanching 47,155,081 43,777,673 0.928 
OMP.5G06.01 OSCC LAF with blanching 38,620,888 35,343,308 0.915 
OMP.1F05.01 OSCC LAF no blanching 54,282,689 46,879,883 0.864 
OMP.4D12.01 OSCC LAF no blanching 48,817,534 43,456,523 0.89 
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Figure B.17: PCA result for the first two dimensions from VST transformed read 
counts of keratosis/hyperplasia samples based on LAF pattern. 
Figure B.18: PCA result for the first two dimensions from VST transformed read 
counts of dysplasia samples based on LAF pattern. 
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Figure B.19: PCA result for the first two dimensions from VST transformed read 
counts of keratosis/hyperplasia samples based on LAF pattern. 
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Appendix C 
Table C.1: Differentially expressed genes for LAF vs No LAF with OSCC excluded from PCA 
(positive logFC indicates greater expression in LAF group and vice versa) 
Gene ID HGNC symbol Average expression logFC Adjusted P value 
55065 SLC52A1 -0.72 -2.15 3.36E-02 
146395 GSG1L -0.23 -1.84 3.03E-02 
100134361 LOC100134361 0.32 -1.45 3.09E-02 
6006 RHCE -0.60 -1.40 3.36E-02 
8733 GPAA1 4.02 -1.25 3.36E-02 
25790 CCDC19 0.68 -1.14 3.38E-02 
116349 C5orf55 0.78 -1.08 3.36E-02 
80045 GPR157 2.84 -0.96 3.64E-02 
221154 MICU2 3.36 0.79 3.36E-02 
353 APRT 6.33 -0.79 3.36E-02 
84954 MPND 3.26 -0.77 3.36E-02 
348180 CTU2 2.56 -0.74 3.36E-02 
64118 DUS1L 5.12 -0.71 3.43E-02 
60560 NAA35 3.44 0.65 3.36E-02 
29988 SLC2A8 2.64 -0.64 4.66E-02 
115939 TSR3 3.51 -0.60 3.36E-02 
8625 RFXANK 4.26 -0.60 3.36E-02 
8751 ADAM15 7.64 -0.59 3.36E-02 
27037 TRMT2A 4.28 -0.57 3.36E-02 
6093 ROCK1 4.67 0.56 3.36E-02 
5108 PCM1 5.98 0.53 3.03E-02 
126626 GABPB2 2.84 -0.49 3.38E-02 
261734 NPHP4 3.68 -0.49 3.36E-02 
5681 PSKH1 4.69 -0.48 3.36E-02 
 
 
Table C.2: Differentially expressed genes for LAF vs No LAF with OSCC and lichenoid samples 
excluded from PCA (positive logFC indicates greater expression in LAF group and vice versa) 
Gene ID HGNC symbol Average expression logFC Adjusted P value 
221154 MICU2 3.28 0.92 4.88E-02 
84954 MPND 3.19 -0.89 4.88E-02 
6093 ROCK1 4.49 0.61 4.88E-02 
5108 PCM1 5.88 0.58 4.88E-02 
9475 ROCK2 4.65 0.57 4.88E-02 
51520 LARS 5.76 0.49 4.88E-02 
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Table C.3: Top genes identified by sPLS-DA to differentiate samples with and without LAF after 
excluding OSCC 
Gene ID HGNC symbol LAF mean No LAF mean logFC LAF – No LAF 
146395 GSG1L 4.72 6.09 -1.37 
55065 SLC52A1 4.45 5.78 -1.33 
100134361 LOC100134361 5.12 6.37 -1.25 
8733 GPAA1 8.48 9.64 -1.16 
25790 CCDC19 5.47 6.47 -1.00 
728882 FAM182A 3.55 4.53 -0.98 
6006 RHCE 4.52 5.50 -0.97 
80045 GPR157 7.40 8.35 -0.95 
116349 C5orf55 5.57 6.46 -0.89 
57165 GJC2 4.72 5.60 -0.88 
1632 ECI1 8.20 9.04 -0.84 
6606 SMN2 4.48 3.70 0.78 
56731 SLC2A4RG 9.83 10.60 -0.78 
348180 CTU2 7.18 7.94 -0.77 
 
Table C.4: Top genes identified by sPLS-DA to differentiate samples with and without LAF after 
excluding OSCC and lichenoid samples 
Gene ID HGNC symbol LAF mean No LAF mean logFC LAF – No LAF 
8733 GPAA1 8.50 9.92 -1.42 
5013 OTX1 4.16 5.57 -1.42 
100134361 LOC100134361 5.19 6.56 -1.37 
146433 IL34 7.78 9.12 -1.35 
285555 STPG2 3.10 4.22 -1.12 
6006 RHCE 4.58 5.65 -1.07 
5178 ZIM2 7.86 6.84 1.02 
80045 GPR157 7.56 8.57 -1.01 
5003 SLC22A18AS 4.26 5.23 -0.97 
1632 ECI1 8.32 9.26 -0.94 
348180 CTU2 7.19 8.11 -0.93 
84954 MPND 7.79 8.71 -0.92 
6606 SMN2 4.48 3.57 0.92 
9145 SYNGR1 8.61 9.52 -0.92 
221154 MICU2 8.42 7.53 0.89 
144717 FAM109A 8.18 9.06 -0.88 
79169 C1orf35 7.04 7.89 -0.85 
997 CDC34 9.40 10.25 -0.85 
64118 DUS1L 9.73 10.51 -0.79 
29988 SLC2A8 7.23 8.01 -0.78 
9121 SLC16A5 7.65 8.42 -0.78 
129138 ANKRD54 7.79 8.56 -0.77 
5270 SERPINE2 8.56 7.80 0.76 
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Table C.5: Top genes identified by sPLS-DA to differentiate keratosis/hyperplasia without LAF and 
LAF with no blanching (NB = no blanching) 
Gene ID HGNC symbol No LAF mean LAF NB mean logFC No LAF – LAF NB 
161582 DYX1C1 2.70 4.50 -1.80 
400685 CTC-523E23.4 2.35 4.09 -1.74 
10563 CXCL13 4.01 2.35 1.66 
338433 SNORD115-1 4.25 2.66 1.58 
8677 STX10 10.16 8.64 1.52 
100132183 FP6628 5.24 6.74 -1.50 
159 ADSS 7.53 9.00 -1.47 
84954 MPND 9.01 7.60 1.41 
26973 CHORDC1 6.16 7.52 -1.36 
100131131 LOC100131131 3.77 2.46 1.32 
116349 C5orf55 6.85 5.55 1.30 
79777 ACBD4 7.77 6.50 1.28 
989 Sep-07 9.16 10.35 -1.19 
60560 NAA35 7.44 8.60 -1.17 
221154 MICU2 7.39 8.55 -1.16 
3329 HSPD1 8.94 10.04 -1.09 
23259 DDHD2 7.81 8.90 -1.09 
9774 BCLAF1 9.46 10.53 -1.08 
135228 CD109 10.33 11.40 -1.07 
135293 PM20D2 7.02 8.09 -1.06 
79677 SMC6 7.73 8.78 -1.06 
9399 STOML1 7.82 6.77 1.05 
11260 XPOT 8.63 9.65 -1.02 
219844 HYLS1 5.49 6.48 -0.99 
60496 AASDHPPT 7.60 8.58 -0.98 
22876 INPP5F 7.28 8.24 -0.96 
23167 EFR3A 9.36 10.29 -0.94 
6738 TROVE2 8.56 9.49 -0.93 
10606 PAICS 8.38 9.31 -0.93 
8065 CUL5 8.79 9.72 -0.92 
1059 CENPB 11.61 10.70 0.92 
25771 TBC1D22A 9.93 9.04 0.88 
1611 DAP 9.96 9.08 0.88 
727936 GXYLT2 5.96 5.08 0.87 
134510 UBLCP1 7.62 8.49 -0.87 
10313 RTN3 8.74 9.61 -0.86 
8545 CGGBP1 8.60 9.44 -0.84 
116254 GINM1 7.56 8.35 -0.80 
6302 TSPAN31 9.25 8.46 0.80 
79893 GGNBP2 8.39 9.18 -0.79 
65094 JMJD4 7.13 6.35 0.78 
8087 FXR1 8.72 9.48 -0.76 
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Table C.6: Top genes identified by sPLS-DA to differentiate keratosis/hyperplasia without LAF and 
LAF with blanching (B = blanching) 
Gene ID HGNC symbol No LAF mean LAF B mean logFC No LAF - LAF B 
161582 DYX1C1 2.70 4.56 -1.86 
5996 RGS1 5.23 7.06 -1.83 
51733 UPB1 2.35 4.14 -1.79 
338433 SNORD115-1 4.25 2.49 1.75 
400685 CTC-523E23.4 2.35 4.05 -1.70 
1002 CDH4 2.35 4.05 -1.70 
10563 CXCL13 4.01 5.64 -1.63 
219970 GLYATL2 2.76 4.34 -1.58 
28559 TRBV28 2.59 4.04 -1.45 
100506718 FLRT2 3.04 4.47 -1.44 
445347 TRGC1 2.35 3.73 -1.39 
10082 GPC6 5.16 6.52 -1.36 
1404 HAPLN1 2.80 4.15 -1.35 
1646 AKR1C2 9.66 8.32 1.34 
29851 ICOS 3.73 5.05 -1.33 
100131131 LOC100131131 3.77 2.47 1.30 
84954 MPND 9.01 7.76 1.25 
54596 L1TD1 2.35 3.59 -1.24 
116349 C5orf55 6.85 5.61 1.24 
1493 CTLA4 4.43 5.62 -1.19 
2877 GPX2 10.32 9.20 1.12 
159 ADSS 7.53 8.65 -1.12 
79777 ACBD4 7.77 6.66 1.11 
93426 SYCE1 2.67 3.77 -1.10 
79677 SMC6 7.73 8.80 -1.07 
8677 STX10 10.16 9.10 1.06 
4345 CD200 5.39 6.45 -1.05 
23259 DDHD2 7.81 8.86 -1.05 
989 Sep-07 9.16 10.18 -1.02 
60560 NAA35 7.44 8.42 -0.98 
644554 CTD-2554C21.2 2.35 3.29 -0.95 
1059 CENPB 11.61 10.70 0.91 
22876 INPP5F 7.28 8.18 -0.89 
60496 AASDHPPT 7.60 8.47 -0.87 
221154 MICU2 7.39 8.25 -0.86 
10882 C1QL1 2.35 3.19 -0.85 
135228 CD109 10.33 11.17 -0.84 
23483 TGDS 5.87 6.71 -0.84 
346689 KLRG2 6.78 5.95 0.83 
26973 CHORDC1 6.16 6.99 -0.82 
124975 GGT6 10.94 10.14 0.79 
7570 ZNF22 5.58 6.37 -0.79 
285761 DCBLD1 6.91 7.69 -0.78 
1611 DAP 9.96 9.18 0.78 
134510 UBLCP1 7.62 8.38 -0.76 
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Table C.7: Top genes identified by sPLS-DA to differentiate keratosis/hyperplasia with and without 
blanching (NB = no blanching, B = blanching) 
Gene ID HGNC symbol LAF NB mean LAF B mean logFC LAF NB – LAF B 
10563 CXCL13 2.35 5.64 -3.29 
1646 AKR1C2 10.36 8.32 2.04 
10082 GPC6 4.59 6.52 -1.93 
1493 CTLA4 3.86 5.62 -1.76 
2877 GPX2 10.95 9.20 1.75 
29851 ICOS 3.41 5.05 -1.64 
100506718 FLRT2 2.88 4.47 -1.59 
28559 TRBV28 2.50 4.04 -1.54 
5996 RGS1 5.56 7.06 -1.50 
54504 CPVL 7.49 8.94 -1.45 
727936 GXYLT2 5.08 6.50 -1.41 
4345 CD200 5.08 6.45 -1.36 
1002 CDH4 2.73 4.05 -1.32 
1404 HAPLN1 2.83 4.15 -1.31 
93426 SYCE1 2.50 3.77 -1.27 
51733 UPB1 2.87 4.14 -1.26 
3486 IGFBP3 11.37 10.15 1.22 
346689 KLRG2 7.12 5.95 1.17 
285513 GPRIN3 6.62 7.78 -1.16 
55966 AJAP1 4.85 6.01 -1.16 
54596 L1TD1 2.43 3.59 -1.16 
219970 GLYATL2 3.18 4.34 -1.15 
100507673 NA 2.43 3.55 -1.12 
285761 DCBLD1 6.64 7.69 -1.05 
100132183 FP6628 6.74 5.72 1.02 
10220 GDF11 5.89 6.83 -0.94 
100422976 MIR4256 3.58 2.64 0.94 
445347 TRGC1 2.81 3.73 -0.93 
28730 TRAJ25 2.35 3.24 -0.89 
124975 GGT6 11.03 10.14 0.88 
10882 C1QL1 2.35 3.19 -0.85 
8935 SKAP2 7.05 7.89 -0.84 
9459 ARHGEF6 7.81 8.62 -0.81 
644554 CTD-2554C21.2 2.48 3.29 -0.81 
2053 EPHX2 10.02 9.21 0.81 
5295 PIK3R1 9.44 10.20 -0.76 
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Table C.8: Top genes identified by sPLS-DA to differentiate dysplasia without LAF and LAF with 
no blanching (NB = no blanching) 
Gene ID HGNC symbol No LAF mean LAF NB mean logFC No LAF – LAF NB 
9721 GPRIN2 8.59 6.45 2.14 
5540 AC244230.2 5.56 3.56 2.00 
3952 LEP 2.78 4.43 -1.65 
654342 AC027612.6 5.96 4.35 1.62 
100288069 RP11-206L10.2 2.83 4.28 -1.45 
285768 LOC285768 2.55 3.78 -1.23 
28646 TRAV36DV7 2.35 3.51 -1.16 
3623 INHA 2.51 3.66 -1.15 
3945 LDHB 8.88 10.01 -1.13 
200403 VWA3B 2.46 3.52 -1.06 
100506678 NA 4.53 3.59 0.95 
100134713 NDUFB2-AS1 4.48 3.54 0.94 
100506897 DAPK1-IT1 2.46 3.40 -0.94 
57678 GPAM 7.63 8.56 -0.93 
1280 COL2A1 3.84 2.92 0.92 
84925 DIRC2 9.14 8.22 0.92 
80019 UBTD1 8.24 7.33 0.91 
8722 CTSF 9.24 8.38 0.85 
57799 RAB40C 9.24 8.41 0.84 
80820 EEPD1 9.35 8.51 0.84 
55835 CENPJ 6.44 7.24 -0.81 
4038 LRP4 9.36 8.56 0.80 
29880 ALG5 7.66 8.45 -0.80 
90203 SNX21 9.87 9.07 0.79 
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Table C.9: Top genes identified by sPLS-DA to differentiate dysplasia without LAF and LAF with 
blanching (B = blanching) 
Gene ID HGNC symbol No LAF mean LAF Blanching mean logFC No LAF – LAF B 
554226 ANKRD30BL 13.33 11.08 2.25 
3299 HSF4 8.05 6.40 1.65 
2 A2M 11.91 13.49 -1.58 
7849 PAX8 7.26 5.69 1.57 
5858 PZP 6.74 8.28 -1.54 
440590 ZYG11A 5.27 3.73 1.54 
1281 COL3A1 13.92 15.24 -1.32 
80045 GPR157 8.31 7.03 1.28 
9721 GPRIN2 8.59 7.32 1.27 
6403 SELP 7.89 9.07 -1.18 
100505942 LOC100505942 2.69 3.85 -1.16 
646471 LOC646471 6.31 5.16 1.16 
79854 LINC00115 4.32 3.17 1.15 
22918 CD93 9.88 10.98 -1.10 
161882 ZFPM1 6.28 5.19 1.08 
7075 TIE1 8.64 9.71 -1.07 
55790 CSGALNACT1 8.22 9.27 -1.05 
115950 ZNF653 6.34 5.29 1.04 
5175 PECAM1 8.78 9.81 -1.02 
654342 AC027612.6 5.96 4.97 0.99 
716 C1S 12.00 12.99 -0.99 
5998 RGS3 8.80 9.71 -0.91 
3945 LDHB 8.88 9.77 -0.89 
26039 SS18L1 8.37 7.62 0.75 
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Table C.10: Top genes identified by sPLS-DA to differentiate dysplasia with and without blanching 
(NB = no blanching, B = blanching) 
Gene ID HGNC symbol LAF NB mean LAF B mean logFC LAF NB – LAF B 
554226 ANKRD30BL 12.94 11.08 1.86 
5540 AC244230.2 3.56 5.03 -1.47 
2 A2M 12.23 13.49 -1.26 
100288069 RP11-206L10.2 4.28 3.04 1.24 
3952 LEP 4.43 3.23 1.20 
200403 VWA3B 3.52 2.35 1.17 
646471 LOC646471 6.33 5.16 1.17 
7849 PAX8 6.80 5.69 1.11 
3299 HSF4 7.49 6.40 1.09 
7075 TIE1 8.63 9.71 -1.08 
79854 LINC00115 4.25 3.17 1.08 
6403 SELP 8.01 9.07 -1.06 
28646 TRAV36DV7 3.51 2.45 1.05 
5858 PZP 7.26 8.28 -1.02 
161882 ZFPM1 6.18 5.19 0.99 
440590 ZYG11A 4.68 3.73 0.96 
9721 GPRIN2 6.45 7.32 -0.88 
716 C1S 12.16 12.99 -0.83 
22918 CD93 10.17 10.98 -0.82 
 
Table C.11: Top genes identified by sPLS-DA to differentiate Lichenoid lesions with and without 
blanching (NB = no blanching, B = blanching) 
Gene ID HGNC symbol LAF NB mean LAF B mean logFC LAF NB –LAF B 
390714 LOC390714 3.76924 2.4732 1.29604 
647174 SERPINE3 2.7826 3.951 -1.1684 
100506856 NA 2.84308 3.8484 -1.00532 
100506466 NA 3.45796 2.4538 1.00416 
64146 PDF 4.20484 3.2392 0.96564 
100128593 LOC100128593 3.45676 2.4968 0.95996 
11147 HHLA3 5.31392 4.4636 0.85032 
643699 GOLGA8I 4.44724 5.2912 -0.84396 
100132738 NA 3.58244 4.4242 -0.84176 
60677 CELF6 5.13284 5.9712 -0.83836 
284723 SLC25A34 4.47692 5.2426 -0.76568 
65010 SLC26A6 7.4708 8.235 -0.7642 
 
